<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease - Sinopoulou, V - 2021 | Cochrane Library</title> <meta content="Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease - Sinopoulou, V - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013531.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease - Sinopoulou, V - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013531.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013531.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease" name="citation_title"/> <meta content="Vassiliki Sinopoulou" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Morris Gordon" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Anthony K Akobeng" name="citation_author"/> <meta content="Sidra Medicine" name="citation_author_institution"/> <meta content="aakobeng@sidra.org" name="citation_author_email"/> <meta content="Marco Gasparetto" name="citation_author"/> <meta content="The Royal London Hospital, Bart's Health Trust" name="citation_author_institution"/> <meta content="Michael Sammaan" name="citation_author"/> <meta content="Health Education England, North West" name="citation_author_institution"/> <meta content="Jessica Vasiliou" name="citation_author"/> <meta content="Crohn’s and Colitis UK" name="citation_author_institution"/> <meta content="Terence M. Dovey" name="citation_author"/> <meta content="Brunel University London" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD013531.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/11/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013531.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013531.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013531.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Abdominal Pain [etiology, therapy]; *Colitis, Ulcerative; *Crohn Disease [complications]; *Inflammatory Bowel Diseases; *Transcranial Direct Current Stimulation" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013531.pub2&amp;doi=10.1002/14651858.CD013531.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Nio3SV1W";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013531\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013531\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013531\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013531\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ko","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013531.pub2",title:"Interventions for the management of abdominal pain in Crohn\u0027s disease and inflammatory bowel disease",firstPublishedDate:"Nov 29, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Nio3SV1W&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013531.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013531.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013531.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013531.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013531.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013531.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013531.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013531.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013531.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013531.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7864 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013531.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-sec-0136"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-sec-0016"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-sec-0130"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/appendices#CD013531-sec-0141"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/table_n/CD013531StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/table_n/CD013531StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/information#CD013531-cr-0004">Vassiliki Sinopoulou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/information#CD013531-cr-0005">Morris Gordon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/information#CD013531-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Anthony K Akobeng</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/information#CD013531-cr-0007">Marco Gasparetto</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/information#CD013531-cr-0008">Michael Sammaan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/information#CD013531-cr-0009">Jessica Vasiliou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013531.pub2/information#CD013531-cr-0010">Terence M. Dovey</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/information/en#CD013531-sec-0145">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 November 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013531.pub2">https://doi.org/10.1002/14651858.CD013531.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013531-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013531-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013531-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013531-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013531-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013531-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013531-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013531-abs-0001" lang="en"> <section id="CD013531-sec-0001"> <h3 class="title" id="CD013531-sec-0001">Background</h3> <p>Crohn's disease is a remitting and relapsing disorder that can affect the whole gastrointestinal tract. Active disease symptoms include abdominal pain, fatigue, weight loss, and diarrhoea. There is no known cure; however, the disease can be managed, and therefore places a huge financial burden on healthcare systems. Abdominal pain is a common and debilitating symptom of Crohn's and other inflammatory bowel diseases (IBDs), and is multifaceted. Abdominal pain in Crohn's disease could be a symptom of disease relapse or related to medication adverse effects, surgical complications and strictures or adhesions secondary to IBD. In the absence of these factors, around 20 to 50% of people with Crohn's in remission still experience pain. </p> </section> <section id="CD013531-sec-0002"> <h3 class="title" id="CD013531-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of interventions for managing abdominal pain in people with Crohn's disease and IBD (where data on ulcerative colitis and Crohn's disease could not be separated). </p> </section> <section id="CD013531-sec-0003"> <h3 class="title" id="CD013531-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, three other databases, and clinical trials registries on 29 April 2021. We also searched the references of trials and systematic reviews for any additional trials. </p> </section> <section id="CD013531-sec-0004"> <h3 class="title" id="CD013531-sec-0004">Selection criteria</h3> <p>All published, unpublished, and ongoing randomised trials that compared interventions for the management of abdominal pain in the setting of Crohn's disease and IBD, with other active interventions or standard therapy, placebo, or no therapy were included. We excluded studies that did not report on any abdominal pain outcomes. </p> </section> <section id="CD013531-sec-0005"> <h3 class="title" id="CD013531-sec-0005">Data collection and analysis</h3> <p>Five review authors independently conducted data extraction and 'Risk of bias' assessment of the included studies. We analysed data using Review Manager 5. We expressed dichotomous and continuous outcomes as risk ratios and mean differences with 95% confidence intervals. We assessed the certainty of the evidence using GRADE methodology. </p> </section> <section id="CD013531-sec-0006"> <h3 class="title" id="CD013531-sec-0006">Main results</h3> <p>We included 14 studies (743 randomised participants).</p> <p>Five studies evaluated participants with Crohn's disease; seven studies evaluated participants with IBD where the data on ulcerative colitis and Crohn's disease could not be separated; and two studies provided separate results for Crohn's disease participants. Studies considered a range of disease activity states. Two studies provided intervention success definitions, whilst the remaining studies measured pain as a continuous outcome on a rating scale. All studies except one measured pain intensity, whilst three studies measured pain frequency. Withdrawals due to adverse events were directly or indirectly reported in 10 studies. </p> <p>No conclusions could be drawn about the efficacy of the majority of the interventions on pain intensity, pain frequency, and treatment success, except for the comparison of transcranial direct current stimulation to sham stimulation. The certainty of the evidence was very low in all but one comparison because of imprecision due to sparse data and risk of bias assessed as unclear or high risk. </p> <p>Two studies compared a low FODMAP diet (n=37) to a sham diet (n=45) in IBD patients. The evidence on pain intensity was of very low certainty (MD ‐12.00, 95% CI ‐114.55 to 90.55). One study reported pain intensity separately for CD participants in the low FODMAP group [n=14, mean(SD)=24 (82.3)] and the sham group [n=12, mean(SD)=32 (69.3)]. The same study also reported pain frequency for IBD participants in the low FODMAP group [n=27, mean(SD)=36 (26)] and sham group [n=25, mean(SD)=38(25)] and CD participants in the low FODMAP group [n=14, mean(SD)=36 (138.4)] and sham group [n=12, mean(SD)=48 (128.2)]. Treatment success was not reported. </p> <p>One study compared a low FODMAP diet (n=25) to high FODMAP/normal diet (n=25) in IBD patients. The data reported on pain intensity was unclear. Treatment success and pain frequency were not reported. </p> <p>One study compared medicine‐separated moxibustion combined with acupuncture (n=51) versus wheat bran‐separated moxibustion combined with shallow acupuncture (n=51) in CD patients. The data reported on pain intensity and frequency were unclear. Treatment success was not reported. </p> <p>One study compared mindfulness with CBT (n=33) versus no treatment (n=33) in IBD patients. The evidence is very uncertain about the effect of this treatment on pain intensity and frequency (MD ‐37.00, 95% CI ‐87.29 to 13.29). Treatment success was not reported. </p> <p>One study compared soft non‐manipulative osteopathic treatment (n=16) with no treatment besides doctor advice (n=14) in CD patients. The evidence is very uncertain about the effect of this treatment on pain intensity (MD 0.01, 95% CI ‐1.81 to 1.83). Treatment success and pain frequency were not reported. </p> <p>One study compared stress management (n=15) to self‐directed stress management(n=15) and to standard treatment (n=15) in CD patients. The evidence is very uncertain about the effect of these treatments on pain intensity (MD ‐30.50, 95% CI ‐58.45 to ‐2.55 and MD ‐34.30, 95% CI ‐61.99 to ‐6.61). Treatment success and pain frequency were not reported. </p> <p>One study compared enteric‐release glyceryl trinitrate (n=34) with placebo (n=36) in CD patients. The data reported on pain intensity was unclear. Treatment success and pain frequency were not reported.  </p> <p>One study compared 100 mg olorinab three times per day (n=8) with 25 mg olorinab three times per day (n=6) in CD patients. Pain intensity was measured as a 30% reduction in weekly average abdominal pain intensity score for the 100mg group (n=5) and the 25mg group (n=6). The evidence is very uncertain about the effect of this treatment on pain intensity (RR 0.66, 95% CI 0.38 to 1.15). Treatment success and pain frequency were not reported. </p> <p>One study compared relaxation training (n=28) to a waitlist (n=28) in IBD patients. The evidence is very uncertain about the effect of this treatment on pain intensity (MD ‐0.72, 95% CI ‐1.85 to 0.41). Treatment success and pain frequency were not reported. </p> <p>One study compared web‐based education (n=30) with a book‐based education (n=30) in IBD patients. The evidence is very uncertain about the effect of this treatment on pain intensity (MD ‐0.13, 95% CI ‐1.25 to 0.99). Treatment success and pain frequency were not reported. </p> <p>One study compared yoga (n=50) with no treatment (n=50) in IBD patients. The data reported on treatment success were unclear. Pain frequency and intensity were not reported. </p> <p>One study compared transcranial direct current stimulation (n = 10) to sham stimulation (n = 10) in IBD patients. There may be an improvement in pain intensity when transcranial direct current is compared to sham stimulation (MD ‐1.65, 95% CI ‐3.29 to ‐0.01, low‐certainty evidence). Treatment success and pain frequency were not reported. </p> <p>One study compared a kefir diet (<i>Lactobacillus</i> bacteria) to no intervention in IBD patients and provided separate data for their CD participants. The evidence is very uncertain about the effect of this treatment on pain intensity in IBD (MD 0.62, 95% CI 0.17 to 1.07) and CD (MD ‐1.10, 95% CI ‐1.67 to ‐0.53). Treatment success and pain frequency were not reported. </p> <p>Reporting of our secondary outcomes was inconsistent.</p> <p>The most adverse events were reported in the enteric‐release glyceryl trinitrate and olorinab studies.  In the enteric‐release glyceryl trinitrate study, the adverse events were higher in the intervention arm. In the olorinab study, more adverse events were observed in the higher dose arm of the intervention.  In the studies on non‐drug interventions, adverse events tended to be very low or zero. However, no clear judgements regarding adverse events can be drawn for any interventions due to the low number of events. </p> <p>Anxiety and depression were measured and reported at the end of intervention in only one study; therefore, no meaningful conclusions can be drawn for this outcome. </p> </section> <section id="CD013531-sec-0007"> <h3 class="title" id="CD013531-sec-0007">Authors' conclusions</h3> <p>We found low certainty evidence that transcranial direct current stimulation may improve pain intensity compared to sham stimulation. We could not reach any conclusions on the efficacy of any other interventions on pain intensity, pain frequency, and treatment success. The certainty of the evidence was very low due to the low numbers of studies and participants in each comparison and clinical heterogeneity amongst the studies. </p> <p>While no serious or total adverse events were elicited explicitly with any of the treatments studied, the reported events were very low. The certainty of the evidence for all comparisons was very low, so no conclusions can be drawn. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013531-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013531-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013531-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013531-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013531-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013531-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013531-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013531-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013531-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013531-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013531-abs-0002" lang="en"> <h3>Treatments for stomach pain in Crohn's disease</h3> <p><b>What is the aim of this review?</b> </p> <p>The aim of this Cochrane Review was to find out whether treatments in people with Crohn's disease can improve stomach pain. </p> <p>We analysed data from 14 studies to answer this question.</p> <p><b>Key messages</b> </p> <p>Based on low‐quality evidence, electrical brain stimulation may improve stomach pain compared to fake brain stimulation. </p> <p>It is unclear whether there is any difference between a low FODMAP (a group of sugars found in food) diet and a diet that is not low in FODMAP in improving stomach pain. </p> <p>It is unclear whether there is any difference between a stress management programme, self‐directed stress management, and standard treatment only, in improving stomach pain. </p> <p>We were unable to draw any conclusions about the safety of any of the interventions.</p> <p>It is unclear whether any of the treatments for the other comparisons under study are better or worse than another, as the evidence was limited due to the very low numbers of studies and participants and low quality of the reporting. </p> <p>Further research that addresses the quality issues we have highlighted is needed.</p> <p><b>What was studied in the review?</b> </p> <p>People with Crohn's disease commonly suffer stomach pain whether their disease is active or inactive. </p> <p>Several types of therapies have been used to try to reduce pain in Crohn's disease, including diets, psychological therapies, alternative therapies, drugs, and exercise therapies. </p> <p>There is currently no agreement amongst healthcare providers as to which therapy is better. </p> <p><b>What are the main results of the review?</b> </p> <p>We searched for randomised controlled trials (studies in which participants are assigned to one of two or more treatment groups using a random method) comparing any treatment with any other treatment (such as dummy/placebo treatments) in people with Crohn's disease. We found 14 trials including a total of 743 participants who were aged 16 to 80 years old. We made the following conclusions. </p> <p>• Electrical brain stimulation may be better than fake brain stimulation in improving pain, based on low‐quality evidence<br/>• It is unclear whether a low FODMAP diet or a diet that is not low in FODMAP is better in improving pain.<br/>• It is unclear whether a stress management programme, self‐directed stress management, or standard treatment only is better in improving pain.<br/>• It is unclear whether there is any difference between any of the other therapies in their effects on the management of pain.<br/>• It is unclear whether any therapy leads to a difference in major and minor side effects. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>This review is up‐to‐date as of April 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013531-sec-0136" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013531-sec-0136"></div> <h3 class="title" id="CD013531-sec-0137">Implications for practice</h3> <section id="CD013531-sec-0137"> <p>Low‐certainty evidence suggests that transcranial direct current stimulation may be effective in improving pain for inflammatory bowel disease patients. </p> <p>No conclusions could be drawn for any of the other interventions either for primary or secondary efficacy outcomes, as the evidence is of very low certainty due to low numbers of participants for each comparison and clinical heterogeneity amongst studies. </p> <p>Whilst no serious or total adverse events were specifically elicited with any of the treatments studied, the numbers of reported events were very low, and the certainty of the evidence was very low for all comparisons, so no conclusions can be drawn. </p> <p>Anxiety and depression were poorly reported, and once again no conclusions can be drawn as to the impact of the included interventions on these outcomes. </p> </section> <h3 class="title" id="CD013531-sec-0138">Implications for research</h3> <section id="CD013531-sec-0138"> <p>The need for future research is clear. Given the prominence of abdominal pain in people with Crohn's disease, randomised controlled trials that target it as an independent condition and not as part of inducing or maintaining remission are numerous, but the nature of the evidence base leads to much justification for further research. Many of the interventions studied in the trials included in this review are used anecdotally by patients and are available without clinician involvement, therefore clear evidence to inform patients when making treatment decisions is vital. </p> <p>No high or moderate certainty conclusions could be reached on the efficacy of any of the interventions included in this review. Transcranial direct current stimulation showed low‐certainty efficacy. Other trials that showed some positive results, albeit with very low‐certainty evidence (<a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>), were in participants that had quiescent disease. Irritable bowel syndrome is more common in inflammatory bowel disease patients, and it is possible that all of these interventions are simply treating irritable bowel syndrome. Any of the included interventions could therefore be targets for future research. </p> <p>Considering the currently ongoing trials identified in this review, they appear to be still very heterogeneous in terms of the range of therapies, with diverse outcome measures and relatively low sample sizes planned, which will limit the impact these studies can have on the evidence base. </p> <p>We suggest that key stakeholders, including clinicians, those with an understanding of health economics, and most importantly patients, consider which interventions are of interest. All of them are particularly well placed to consider feasibility, acceptability, and tolerability amongst other factors in targeting future research. </p> <p>Furthermore, researchers can consider addressing risk of bias in their reporting and reporting data by disease type or severity, or both. </p> <p>The issue of sample size must be highlighted. All of the studies included in this review were very small. We strongly advise the use of indicative odds ratios from this review when performing power calculations. Such accurate calculations are vital to halt the large number of low‐powered studies and include the precision of findings. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013531-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013531-sec-0008"></div> <div class="table" id="CD013531-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Low FODMAP diet compared to sham diet for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Low FODMAP diet compared to sham diet for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease<br/><b>Setting:</b> multicentre, 2 gastroenterology clinics in the UK and an unstated setting in Italy<br/><b>Intervention:</b> low FODMAP diet<br/><b>Comparison:</b> sham diet </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sham diet</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with low FODMAP diet</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Note measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain frequency IBD (measured in days of pain on the IBS‐SSS questionnaire)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2 lower<br/>(15.86 lower to 11.86 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain frequency IBD (measured in days with moderate or severe pain on the GSRS questionnaire)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.4 higher<br/>(0.44 lower to 1.24 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain frequency CD (measured in days of pain on the IBS‐SSS questionnaire)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 12 lower<br/>(114.55 lower to 90.55 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity IBD (0‐10cm visual analogue scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 8.46 lower<br/>(15.76 lower to 1.16 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity IBD (0‐3 point GSRS scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 8 lower<br/>(66.27 lower to 50.27 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity CD (0‐10cm visual analogue scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.2 higher<br/>(8.67 lower to 9.07 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7.4 per 1000</p> <p>(1 to 77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.85 (0.18 to 19.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CD:</b> Crohn's disease; <b>CI:</b> confidence interval; <b>FODMAP:</b> fermentable oligo‐, di‐, monosaccharides and polyols; <b>GSRS:</b> Gastrointestinal Symptom Rating Scale; <b>IBD:</b> inflammatory bowel disease; <b>IBS‐SSS:</b> Irritable Bowel Syndrome Severity Scoring System; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias.<br/><sup>b</sup>Downgraded two levels due to imprecision from very sparse data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013531-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Medicine‐separated moxibustion combined with acupuncture compared with wheat bran‐separated moxibustion combined with shallow acupuncture for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Medicine‐separated moxibustion combined with acupuncture compared with wheat bran‐separated moxibustion combined with shallow acupuncture for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with Crohn's disease </p> <p><b>Settings:</b> Shanghai Acupuncture Meridian Institute Medical Clinic Acupuncture Inflammatory Bowel Disease Specialist Clinic, Zhongshan Hospital Affiliated Endoscopic Center, and Yueyang Hospital, Shanghai University of Traditional Chinese Medicine </p> <p><b>Intervention:</b> medicine‐separated moxibustion combined with acupuncture </p> <p><b>Comparison:</b> wheat bran‐separated moxibustion combined with shallow acupuncture </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with wheat bran‐separated moxibustion combined with shallow acupuncture</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with medicine‐separated moxibustion combined with acupuncture</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain frequency or change in frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain intensity or change in intensity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to imprecision from very sparse data.<br/><sup>b</sup>Downgraded one level due to risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013531-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Mindfulness with cognitive behavioural therapy (CBT) compared with no treatment (both groups received standard medical therapy) for the management of abdominal pain in Crohn's Disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Mindfulness with cognitive behavioural therapy (CBT) versus no treatment (both groups received standard medical therapy) for the management of abdominal pain in Crohn's Disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease<br/><b>Setting:</b> multicentre, hospitals in the UK<br/><b>Intervention:</b> mindfulness with CBT<br/><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard medical therapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with mindfulness with CBT + standard medical therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain frequency and intensity (measured as part of the 0‐500 point IBS‐SSS questionnaire)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 37 lower<br/>(87.29 lower to 13.29 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CBT:</b> cognitive behavioural therapy; <b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to imprecision from very sparse data.<br/><sup>b</sup>Downgraded one level due to risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013531-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">soft non‐manipulative osteopathic treatment compared to no intervention for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Soft non‐manipulative osteopathic treatment compared to no intervention for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with Crohn's disease<br/><b>Setting:</b> single centre, hospital in Spain<br/><b>Intervention:</b> soft non‐manipulative osteopathic<br/><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with soft non‐manipulative osteopathic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain frequency or change in frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity (0‐10cm visual analogue scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 higher<br/>(1.81 lower to 1.83 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to imprecision from very sparse data.<br/><sup>b</sup>Downgraded one level due to risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013531-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Directed stress management (it is unclear whether these interventions replaced standard treatment or were added to standard treatment) versus standard treatment for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Stress management (it is unclear whether these interventions replaced standard treatment or were added to standard treatment) versus standard treatment for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with Crohn's disease<br/><b>Setting:</b> single centre, Inflammatory Intestinal Disease Unit of Asturias Central Hospital, Spain<br/><b>Intervention:</b> stress management<br/><b>Comparison:</b> no stress management </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no stress management</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with stress management</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain frequency or change in pain frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity (author‐derived formula based on a 1‐3 point scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 34.3 lower<br/>(61.99 lower to 6.61 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawals due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to imprecision from very sparse data.<br/><sup>b</sup>Downgraded one level due to risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013531-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Self‐directed stress management (it is unclear whether these interventions replaced standard treatment or were added to standard treatment) versus standard treatment for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Self‐directed stress management (it is unclear whether these interventions replaced standard treatment or were added to standard treatment) versus standard treatment for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with Crohn's disease<br/><b>Setting:</b> single centre, Inflammatory Intestinal Disease Unit of Asturias Central Hospital, Spain<br/><b>Intervention:</b> stress management<br/><b>Comparison:</b> no stress management </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no stress management</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with stress management</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain frequency or change in pain frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity  (author‐derived formula based on a 1‐3 point scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 30.5 lower<br/>(58.45 lower to 2.55 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low<sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawals due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to imprecision from very sparse data.<br/><sup>b</sup>Downgraded one level due to risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013531-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Enteric‐release glyceryl trinitrate compared to placebo for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Enteric‐release glyceryl trinitrate compared to placebo for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with Crohn's disease<br/><b>Setting:</b> unstated (centres in the UK)<br/><b>Intervention:</b> enteric‐release glyceryl trinitrate<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with enteric‐release glyceryl trinitrate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain frequency or change in frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain intensity or change in intensity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.18<br/>(0.94 to 10.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>IG: Headache = 1, worsening clinical condition = 4, generalised rash = 1, mood change/irritability = 1, loss of consciousness/memory = 1 </p> <p>CG: Headache = 2, worsening clinical condition = 1</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265 per 1000<br/>(78 to 897) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias.<br/><sup>b</sup>Downgraded two levels due to imprecision from very sparse data. </p> <p>IG: Intervention group</p> <p>CG: Control group</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013531-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">100 mg olorinab 3 times/day compared to 25 mg olorinab 3 times/day for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>100 mg olorinab 3 times/day compared to 25 mg olorinab 3 times/day for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with Crohn's disease<br/><b>Setting:</b> unstated (multicentre, USA)<br/><b>Intervention:</b> 100 mg olorinab 3 times/day<br/><b>Comparison:</b> 25 mg olorinab 3 times/day </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with 25 mg olorinab 3 times/day</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with 100 mg olorinab 3 times/day</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain frequency or change in pain frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain intensity (30% reduction in weekly AAPS)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/>(0.38 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>660 per 1000<br/>(380 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias.<br/><sup>b</sup>Downgraded two levels due to imprecision from very sparse data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013531-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Relaxation training compared to waitlist for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Relaxation training compared to waitlist for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease<br/><b>Setting:</b> Hadassah Medical Center in Jerusalem<br/><b>Intervention:</b> relaxation training<br/><b>Comparison:</b> waitlist </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with waitlist</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with relaxation training</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain frequency or change in pain frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity (0‐10cm visual analogue scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.72 lower<br/>(1.85 lower to 0.41 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawals due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias.<br/><sup>b</sup>Downgraded two levels due to imprecision from very sparse data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013531-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Web‐based education compared to standard book‐based education for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Web‐based education compared to standard book‐based education for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease<br/><b>Setting:</b> single centre, gastroenterology unit in Turkey<br/><b>Intervention:</b> web‐based education<br/><b>Comparison:</b> standard book‐based education </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard book‐based education</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with web‐based education</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain frequency or change in frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity (0‐10cm visual analogue scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.13 lower<br/>(1.25 lower to 0.99 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias.<br/><sup>b</sup>Downgraded two levels due to imprecision from very sparse data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013531-tbl-0011"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Yoga intervention compared to no treatment (both groups received standard medical therapy) for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Yoga intervention compared to no treatment (both groups received standard medical therapy) for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with inflammatory bowel disease </p> <p><b>Settings:</b> single centre, All India Institute of Medical Science (AIIMS), New Delhi, India </p> <p><b>Intervention:</b> yoga </p> <p><b>Comparison:</b> no yoga </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard medical therapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with yoga plus standard medical therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain frequency or change in frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain intensity or change in intensity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias.<br/><sup>b</sup>Downgraded two levels due to imprecision from very sparse data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013531-tbl-0012"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Transcranial direct current stimulation compared to sham stimulation for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Transcranial direct current stimulation compared to sham stimulation for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease<br/><b>Setting:</b> single centre, Medical Department I (Gastroenterology, Infectious Diseases, Rheumatology) of the Charite‐Campus Benjamin Franklin, Germany<br/><b>Intervention:</b> transcranial direct current stimulation<br/><b>Comparison:</b> sham stimulation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sham stimulation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with transcranial direct current stimulation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain frequency or change in frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity (0‐10cm visual analogue scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.65 lower<br/>(3.29 lower to 0.01 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>PPT:</b> Pressure Pain Threshold </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to imprecision from very sparse data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013531-tbl-0013"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Kefir ( Lactobacillus bacteria) compared to no intervention for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Kefir (<i>Lactobacillus</i> bacteria) compared to no intervention for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with inflammatory bowel disease </p> <p><b>Setting:</b> unstated (single centre, Turkey) </p> <p><b>Intervention:</b> kefir </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with kefir</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain frequency or change in frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity IBD  (4‐point rating scale from 0 to 3)</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.62 higher<br/>(0.17 higher to 1.07 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>very low <sup>a b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity CD (4‐point rating scale from 0 to 3)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> <p> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.10 lower<br/>(1.67 lower to 0.53 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CD:</b> Crohn's disease; <b>CI:</b> confidence interval; <b>IBD:</b> inflammatory bowel disease; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias.<br/><sup>b</sup>Downgraded two levels due to imprecision from very sparse data. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013531-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013531-sec-0009"></div> <section id="CD013531-sec-0010"> <h3 class="title" id="CD013531-sec-0010">Description of the condition</h3> <p>Inflammatory Bowel Disease (IBD) is a term for a group of disorders characterised by inflammation of the gut. The two main types of IBD are Crohn's Disease (CD) and Ulcerative Colitis (UC), which have several subtypes based on onset, disease location and clinical behaviour for CD, and extent for UC. There also exists a categorisation for the much rarer condition indeterminate colitis (<a href="./references#CD013531-bbs2-0080" title="SatsangiJ , SilverbergMS , VermeireS , ColombelJF . The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut2006;55(6):749-53.">Satsangi 2006</a>). </p> <p>CD is a remitting and relapsing disease of the gastrointestinal tract that affects over 3.5 million young people and adults in the USA and Europe (<a href="./references#CD013531-bbs2-0068" title="KaplanG . The global burden of IBD: from 2015 to 2025. Nature Reviews. Gastroenterology &amp; Hepatology2015;12:720-7.">Kaplan 2015</a>), and more than 6.8 million globally (<a href="./references#CD013531-bbs2-0051" title="AlatabS , SepanlouSG , IkutaK , VahediH , BisignanoC , SafiriS , et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterology &amp; Hepatology2020;5(1):17-30.">Alatab 2020</a>). Active CD symptoms include abdominal pain, fatigue, weight loss, and diarrhoea. There is no known cure; however, the disease can be managed via lifelong treatment and care, and therefore places a huge financial burden on healthcare systems. The annual care costs of inflammatory bowel disease (IBD) to the National Health Service (NHS) was estimated at over GBP 1000 million in 2010 (<a href="./references#CD013531-bbs2-0078" title="Royal College of Physicians. Report of the results for the national clinical audit of adult inflammatory bowel disease inpatient care in the UK. https://www.rcplondon.ac.uk › file › download (accessed 5 May 2021).">RCP 2012</a>). For CD alone, this amounts to over GBP 6000 per patient annually (<a href="./references#CD013531-bbs2-0060" title="GhoshN , PremchandP . A UK cost of care model for inflammatory bowel disease. Frontline Gastroenterology2015;6(3):169-74. [DOI: 10.1136/flgastro-2014-100514]">Ghosh 2015</a>). Treatment of the disease may involve surgical intervention or immunosuppression using thiopurines and anti‐tumour necrosis factor (anti‐TNF) medications (<a href="./references#CD013531-bbs2-0061" title="Gjuladin-HellonT , GordonM , Iheozor-EjioforZ , AkobengAK . Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database of Systematic Reviews2019, Issue 6. Art. No: CD008414. [DOI: 10.1002/14651858.CD008414.pub3]">Gjuladin‐Hellon 2019</a>). These interventions aim to induce remission, maintain remission, and manage symptoms (<a href="./references#CD013531-bbs2-0063" title="GreenleyRN , KunzJH , SchurmanJV , SwansonE . Abdominal pain and health related quality of life in pediatric inflammatory bowel disease. Journal of Pediatric Psychology2013;38(1):63-71. [DOI: 10.1093/jpepsy/jss097]">Greenley 2013</a>). </p> <p>Abdominal pain is a common and debilitating symptom of CD and other IBDs, which is multifaceted, with multiple causes and contributors, such as a symptom of disease relapse, an adverse effect of medication, surgical complication, or due to problems related to CD itself, such as strictures or adhesions secondary to IBD (<a href="./references#CD013531-bbs2-0081" title="SrinathAI , WalterC , NewaraMC , SzigethyEM . Pain management in patients with inflammatory bowel disease: insights for the clinician. Therapeutic Advances in Gastroenterology2012;5(5):339-57. [DOI: 10.1177/1756283X12446158]">Srinath 2012</a>). The pain may also vary between adults and children and may also be influenced by disease activity. Even in the absence of the aforementioned factors, around 20% to 50% of people with CD in remission still experience pain (<a href="./references#CD013531-bbs2-0052" title="BielefeldtK , DavisB , BinionDG . Pain and inflammatory bowel disease. Inflammatory Bowel Diseases2009;15(5):778-88. [DOI: 10.1002/ibd.20848]">Bielefeldt 2009</a>). This has been attributed to functional abdominal pain disorders (FAPD) such as irritable bowel syndrome (IBS), abdominal migraine, and functional dyspepsia (<a href="./references#CD013531-bbs2-0074" title="OdesS , FrigerM , SergienkoR , SchwartzD , SaridO , Slonim-NevoV , et al. Simple pain measures reveal psycho-social pathology in patients with Crohn's disease. World Journal of Gastroenterology2017;23(6):1076-89. [DOI: 10.3748/wjg.v23.i6.1076]">Odes 2017</a>), although the definition of such disorders involves explicit exclusion of pathology such as IBD. Evidence is lacking to indicate whether there is a specific variant of functional pain coexisting within people with IBD, or a separate pain disorder that can be attributed to IBD pathologic mechanisms. The aetiology and management of abdominal pain in CD may therefore vary in ways that cannot be fully explained. A common suggestion is that the inflammation in the intestinal wall can lead to the perception of abdominal pain (<a href="./references#CD013531-bbs2-0055" title="DochertyMJ , Jones RCW 3rd, WallaceMS . Managing pain in inflammatory bowel disease. Gastroenterology &amp; Hepatology2011;7(9):592.">Docherty 2011</a>). </p> </section> <section id="CD013531-sec-0011"> <h3 class="title" id="CD013531-sec-0011">Description of the intervention</h3> <section id="CD013531-sec-0012"> <h4 class="title">Pharmacological interventions</h4> <p>Medication for CD can reduce inflammation and associated pain by inducing remission. Where pain persists in the absence of inflammation, it has been managed with a variety of agents, including pain‐relieving medication such as antispasmodics, non‐steroidal anti‐inflammatory drugs (NSAIDs), laxatives, antidepressants, antiemetic agents, cyclo‐oxygenase‐2 (COX‐2) inhibitors, and psychoactive drugs such as cannabis and opioids (<a href="./references#CD013531-bbs2-0081" title="SrinathAI , WalterC , NewaraMC , SzigethyEM . Pain management in patients with inflammatory bowel disease: insights for the clinician. Therapeutic Advances in Gastroenterology2012;5(5):339-57. [DOI: 10.1177/1756283X12446158]">Srinath 2012</a>). Due to the potential adverse effects of some of these drugs, short‐term use is advised. </p> </section> <section id="CD013531-sec-0013"> <h4 class="title">Non‐pharmacological interventions</h4> <p>Non‐pharmacological interventions used in managing pain may include dietary, psychological, lifestyle advice, and alternative medicine. These interventions are considered by some as less invasive and may be used as adjuvant treatment. Cognitive behavioural therapy (CBT), stress management, and coping skills training are the most commonly used psychological interventions. These therapies can be very heterogeneous, therefore it is key to consider the specific evidence and conceptual alignment of the approach delivered to understand 'what' the therapy was, as well as 'whether' it was effective. Alternative treatments such as acupuncture and transcutaneous electrical nerve stimulation, which have been used in other conditions such as IBS, are increasingly used in people with IBD, albeit based on limited evidence (<a href="./references#CD013531-bbs2-0081" title="SrinathAI , WalterC , NewaraMC , SzigethyEM . Pain management in patients with inflammatory bowel disease: insights for the clinician. Therapeutic Advances in Gastroenterology2012;5(5):339-57. [DOI: 10.1177/1756283X12446158]">Srinath 2012</a>). Dietary interventions studied include the avoidance of FODMAP (fermentable oligo‐, di‐, monosaccharides and polyols) and the use of supplements with prebiotic properties; however, the evidence on their effectiveness appears to be weak and conflicting (<a href="./references#CD013531-bbs2-0073" title="NortonC , Czuber-DochanW , ArtomM , SweeneyL , HartA . Systematic review: interventions for abdominal pain management in inflammatory bowel disease. Alimentary Pharmacology &amp; Therapeutics2017;46:115-25.">Norton 2017</a>). </p> <p>Whilst some interventions such as neurochemicals and acupuncture have mostly been used in conditions such as IBS, others such as COX‐2 inhibitors have been associated with little to no effect in IBD (<a href="./references#CD013531-bbs2-0075" title="PaiottiAPR , MarchiP , MiszputenSJ , OshimaCTF , FrancoM , RibeiroDA . The role of nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors on experimental colitis. In Vivo2012;26(3):381-93.">Paiotti 2012</a>). </p> </section> </section> <section id="CD013531-sec-0014"> <h3 class="title" id="CD013531-sec-0014">How the intervention might work</h3> <p>The mechanism of action of different interventions depends on the nature or cause of the abdominal pain. </p> <p>Antispasmodics suppress intestinal spasms which cause pain from inflammation or obstruction (<a href="./references#CD013531-bbs2-0081" title="SrinathAI , WalterC , NewaraMC , SzigethyEM . Pain management in patients with inflammatory bowel disease: insights for the clinician. Therapeutic Advances in Gastroenterology2012;5(5):339-57. [DOI: 10.1177/1756283X12446158]">Srinath 2012</a>). Pain related to strictures can be improved by following a low‐residue diet, which can pass through with ease, thereby preventing intestinal pain (<a href="./references#CD013531-bbs2-0081" title="SrinathAI , WalterC , NewaraMC , SzigethyEM . Pain management in patients with inflammatory bowel disease: insights for the clinician. Therapeutic Advances in Gastroenterology2012;5(5):339-57. [DOI: 10.1177/1756283X12446158]">Srinath 2012</a>). A low FODMAP diet also aims to limit the intake of non‐absorbable nutrients, and has recently gained considerable attention in the management of IBS (<a href="./references#CD013531-bbs2-0077" title="PrinceAC , MyersCE , JoyceT , IrvingP , LomerM , WhelanK . Fermentable carbohydrate restriction (low FODMAP diet) in clinical practice improves functional gastrointestinal symptoms in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2016;22(5):1129-36.">Prince 2016</a>). </p> <p>Psychological techniques such as CBT, mindfulness, and stress management tend to help people with CD change negative behaviours that might be worsening their pain and provide coping mechanisms (<a href="./references#CD013531-bbs2-0073" title="NortonC , Czuber-DochanW , ArtomM , SweeneyL , HartA . Systematic review: interventions for abdominal pain management in inflammatory bowel disease. Alimentary Pharmacology &amp; Therapeutics2017;46:115-25.">Norton 2017</a>). Yoga‐based programmes are thought to work by improving depression and anxiety (<a href="./references#CD013531-bbs2-0059" title="EwaisT , BegunJ , KennyM , RickettK , HayK , AjilchiB , et al. A systematic review and meta-analysis of mindfulness based interventions and yoga in inflammatory bowel disease. Journal of Psychosomatic Research2019;116:44-53.">Ewais 2019</a>). Other complementary or alternative therapies, such as the use of herbal and dietary supplements, traditional Chinese practices, and mind‐body techniques, have been proposed to have anti‐inflammatory, stress‐reducing, or other therapeutic modes of action (<a href="./references#CD013531-bbs2-0070" title="LinSC , CheifetzAS . The use of complementary and alternative medicine in patients with inflammatory bowel disease. Gastroenterology and Hepatology2018;14(7):415-25.">Lin 2018</a>). </p> </section> <section id="CD013531-sec-0015"> <h3 class="title" id="CD013531-sec-0015">Why it is important to do this review</h3> <p>Abdominal pain in people with CD can lead to depressive symptoms, reduced quality of life, and an increase in the use of healthcare facilities (<a href="./references#CD013531-bbs2-0081" title="SrinathAI , WalterC , NewaraMC , SzigethyEM . Pain management in patients with inflammatory bowel disease: insights for the clinician. Therapeutic Advances in Gastroenterology2012;5(5):339-57. [DOI: 10.1177/1756283X12446158]">Srinath 2012</a>). Effective pain management is therefore vital. </p> <p>There are concerns regarding the safety of pharmacological interventions, such as the relative inefficacy of currently available analgesics and their potential toxicity. Opioids can offer short‐term relief; however, they are associated with such problems as narcotic bowel syndrome and other symptoms like constipation (<a href="./references#CD013531-bbs2-0082" title="ThapaN , KappusM , HurtR , DiamondS . Implications of the opioid epidemic for the clinical gastroenterology practice. Current Gastroenterology Reports2019;21(9):44.">Thapa 2019</a>). Furthermore, there may be concern amongst people with IBD about the stigma of addiction associated with the use of opioids. The use of opioids in chronic pain can lead to people exhibiting withdrawal symptoms that are similar to CD symptoms (<a href="./references#CD013531-bbs2-0076" title="PaulyNJ , MichailidisL , KindredMG , FlomenhoftD , LofwallMR , WalshSL , et al. Predictors of chronic opioid use in newly diagnosed Crohn's disease. Inflammatory Bowel Diseases2017;23(6):1004-10. [DOI: 10.1097/MIB.0000000000001087]">Pauly 2017</a>), which can further complicate treatment. There are also concerns about the use of NSAIDs, which can have effects that mimic or potentially exacerbate CD activity (<a href="./references#CD013531-bbs2-0071" title="LongMD , KappelmanMD , MartinCF , ChenW , AntonK , SandlerRS . Role of non-steroidal anti-inflammatory drugs in exacerbations of inflammatory bowel disease. Journal of Clinical Gastroenterology2016;50(2):152.">Long 2016</a>). </p> <p>Pain management has been highlighted as a priority topic for research by IBD patient groups and charities, but is currently not covered in the National Institute for Health and Care Excellence guidelines (<a href="./references#CD013531-bbs2-0072" title="National Institute for Health and Care Excellence. Crohn's disease: management. www.nice.org.uk/guidance/ng129 (accessed 1 July 2019).">NICE 2019</a>), European Crohn's and Colitis Organisation guidelines (<a href="./references#CD013531-bbs2-0056" title="DignassA , Van AsscheG , LindsayJO , LemmanM , SöderholmJ , ColombelJF , et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. Journal of Crohn's and Colitis2010;4(1):28-62. [DOI: 10.1016/j.crohns.2009.12.002]">ECCO 2010</a>), or Crohn's and Colitis Foundation guidance. Whilst several non‐Cochrane systematic reviews have assessed interventions for pain management in IBD, none has currently assessed the efficacy and safety of these interventions in Crohn's disease. Although this review covers interventions that have been previously assessed in published Cochrane Reviews in the group portfolio (<a href="./references#CD013531-bbs2-0066" title="Iheozor-EjioforZ , GordonM , CleggA , FreemanSC , Gjuladin-HellonT , MacDonaldJK , et al. Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta-analysis. Cochrane Database of Systematic Reviews2019, Issue 9. Art. No: CD013210. [DOI: 10.1002/14651858.CD013210.pub2]">Iheozor‐Ejiofor 2019</a>; <a href="./references#CD013531-bbs2-0067" title="KafilTS , NguyenTM , MacDonaldJK , ChandeN . Cannabis for the treatment of Crohn's disease. Cochrane Database of Systematic Reviews2018, Issue 11. Art. No: CD012853. [DOI: 10.1002/14651858.CD012853.pub2]">Kafil 2018</a>; <a href="./references#CD013531-bbs2-0069" title="LimketkaiBN , Iheozor-EjioforZ , Gjuladin-HellonT , ParianA , MatareseLE , BracewellK , et al. Dietary interventions for induction and maintenance of remission in inflammatory bowel disease. Cochrane Database of Systematic Reviews2019, Issue 2. Art. No: CD012839. [DOI: 10.1002/14651858.CD012839.pub2]">Limketkai 2019</a>; <a href="./references#CD013531-bbs2-0083" title="TimmerA , PreissJC , MotschallE , RückerG , JantschekG , MoserG . Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database of Systematic Reviews2011, Issue 2. Art. No: CD006913. [DOI: 10.1002/14651858.CD006913.pub2]">Timmer 2011</a>), the focus of this review was only on studies that have been conducted for the purpose of providing relief for abdominal pain. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013531-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013531-sec-0016"></div> <p>To assess the efficacy and safety of interventions for managing abdominal pain in people with Crohn's disease and IBD (where data on ulcerative colitis and Crohn's disease could not be separated). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013531-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013531-sec-0017"></div> <section id="CD013531-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013531-sec-0019"> <h4 class="title">Types of studies</h4> <p>All published, unpublished, and ongoing randomised controlled trials (RCTs) that compared interventions for the management of abdominal pain in the setting of CD and IBD, with other active interventions or standard therapy, placebo, or no therapy. We excluded studies that did not report on any abdominal pain outcomes. </p> </section> <section id="CD013531-sec-0020"> <h4 class="title">Types of participants</h4> <p>Adults and children with Crohn's disease or IBD who are experiencing abdominal pain. If studies included participants with ulcerative colitis as well as those with CD, these studies were included, and separate data sought for analysis. Where separate data could not be obtained, IBD patients were included as a whole. </p> </section> <section id="CD013531-sec-0021"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD013531-list-0001"> <li> <p>Pain‐relieving drugs such as antispasmodics, antidepressants, laxatives, antidiarrhoeal agents, antibiotics, analgesics, antireflux agents, antiemetic agents, antimigraine agents, antihistaminic agents, serotonergic agents, and psychoactive drugs. </p> </li> <li> <p>Behaviour therapy, e.g. cognitive behavioural therapy (CBT), hypnotherapy.</p> </li> <li> <p>Lifestyle advice, e.g. advice on physical activity including exercise.</p> </li> <li> <p>Dietary interventions such as reduced intake of FODMAP; additional fibre intake; decrease in gas‐producing foods; extra fluid intake; lactulose‐, gluten‐, and histamine‐free diet. </p> </li> <li> <p>Pre‐ and probiotics.</p> </li> <li> <p>Other alternative therapies, e.g. acupuncture, homeopathy, body‐oriented therapy, musculoskeletal therapy (osteopathy/chiropractic), yoga. </p> </li> </ul> </p> </section> <section id="CD013531-sec-0022"> <h4 class="title">Types of outcome measures</h4> <p>Both dichotomous and continuous outcomes were valid for inclusion.</p> <section id="CD013531-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013531-list-0002"> <li> <p>Treatment success as defined by the authors.</p> </li> <li> <p>Abdominal pain frequency or change in frequency of pain using any validated scale.</p> </li> <li> <p>Abdominal pain intensity or change in pain intensity using any validated scale.</p> </li> <li> <p>Withdrawal due to adverse events.</p> </li> </ul> </p> </section> <section id="CD013531-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013531-list-0003"> <li> <p>Anxiety/depression using any validated scale.</p> </li> <li> <p>Adverse events (total number of participants with any event).</p> </li> <li> <p>Serious adverse events (as defined by the authors within the primary study)</p> </li> </ul> </p> </section> </section> </section> <section id="CD013531-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013531-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources from the inception of each database to the date of search on 29 April 2021: </p> <p> <ul id="CD013531-list-0004"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) (via Ovid EBMR) (inception to Issue 03, 2021); </p> </li> <li> <p>MEDLINE (via Ovid) (1946 to 29 April 2021);</p> </li> <li> <p>PsycINFO (via Ovid) (1987 to 29 April 2021);</p> </li> <li> <p>AMED (via Ovid) (Allied and Complementary Medicine) (1985 to 29 April 2021);</p> </li> <li> <p>CINAHL (via EBSCO) (Cumulative Index to Nursing and Allied Health Literature) (1984 to 29 April 2021). </p> </li> </ul> </p> <p>We also searched the following trial registers on 29 April 2021:</p> <p> <ul id="CD013531-list-0005"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">www.who.int/trialsearch/</a>). </p> </li> </ul> </p> <p>We placed no restrictions on language of publication. For detailed search strategies, see <a href="./appendices#CD013531-sec-0142">Appendix 1</a>. </p> </section> <section id="CD013531-sec-0027"> <h4 class="title">Searching other resources</h4> <p>As complementary search methods, we carefully checked relevant systematic reviews for potentially eligible studies. We also scrutinised the references of included studies. We sought unpublished trials by contacting experts in the field, and scanned the Internet and abstracts submitted to major international congresses from the three years prior to the search to capture any studies presented but not yet published in full. </p> <p>In the case of foreign language papers, we planned to obtain translations of papers if necessary. </p> </section> </section> <section id="CD013531-sec-0028"> <h3 class="title" id="CD013531-sec-0028">Data collection and analysis</h3> <p>We carried out data collection and analysis according to the methods recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013531-bbs2-0065" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2. Cochrane, 2021.">Higgins 2021</a>). </p> <section id="CD013531-sec-0029"> <h4 class="title">Selection of studies</h4> <p>Five review authors independently screened the titles and abstracts identified by the literature search, excluding studies that based on title and abstract did not meet our inclusion criteria. We obtained the full reports of studies deemed potentially eligible. Five review authors independently assessed the full texts for inclusion in the review. Any disagreements were resolved by discussion or by consulting another review author if necessary. We recorded the studies excluded at this or subsequent stages, and the main reason for their exclusion, in the 'Characteristics of excluded studies' tables. </p> <p>Where there were multiple publications for a given study, we collated the reports of the same study so that each study, rather than each report, was the unit of interest in the review; such studies have a single identifier with multiple references. </p> <p>Studies that had the primary goal of inducing or maintaining remission in IBD were excluded, regardless as to whether they reported pain outcomes. This reflected the fact that any such pain imporvement was as a result of disease state and not an indepedent pain intervention and all such interventions are considered in seperate reviews. Such studies were excluded at the title and abstract screening stage. Studies that did not report any abdominal pain related outcomes, were excluded at the full text screening stage, and only after contact with the authors whenever the reporting of pain related outcomes was unclear. </p> </section> <section id="CD013531-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Five review authors independently performed data extraction using piloted data extraction forms. We extracted the following data from the included studies: </p> <p> <ul id="CD013531-list-0006"> <li> <p>trial setting: country and number of trial centres;</p> </li> <li> <p>methods: study design, total study duration and date;</p> </li> <li> <p>participant characteristics: age, sociodemographics, ethnicity, diagnostic criteria, pain location, and total number of participants; </p> </li> <li> <p>eligibility criteria: inclusion and exclusion criteria;</p> </li> <li> <p>intervention and comparator;</p> </li> <li> <p>outcomes: outcome definition, unit of measurement, and time of collection;</p> </li> <li> <p>results: number of participants allocated to each group, missing participants, and sample size; </p> </li> <li> <p>funding source.</p> </li> </ul> </p> <p>All treatment arms are described in the 'Characteristics of included studies' tables.</p> </section> <section id="CD013531-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Five review authors independently assessed risk of bias in the included studies based on the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013531-bbs2-0065" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2. Cochrane, 2021.">Higgins 2021</a>). We assessed the following 'Risk of bias' domains: </p> <p> <ul id="CD013531-list-0007"> <li> <p>sequence generation (selection bias);</p> </li> <li> <p>allocation concealment (selection bias);</p> </li> <li> <p>blinding of participants and personnel (performance bias);</p> </li> <li> <p>blinding of outcome assessment (detection bias);</p> </li> <li> <p>incomplete outcome data (attrition bias);</p> </li> <li> <p>selective reporting (reporting bias);</p> </li> <li> <p>other bias such as imbalance in participants' baseline characteristics.</p> </li> </ul> </p> <p>We judged the studies to be at low, high, or unclear risk of bias for each domain assessed, based on the guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013531-bbs2-0065" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2. Cochrane, 2021.">Higgins 2021</a>). </p> <p>After data extraction, the five review authors compared the extracted data, discussing and resolving any discrepancies before transfer of data into the 'Characteristics of included studies' tables. </p> </section> <section id="CD013531-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed treatment effect as risk ratios (RR) with corresponding 95% confidence intervals (CI) for dichotomous outcomes, and mean difference (MD) with 95% CI for continuous outcomes. Where endpoint and change score were both reported, we used endpoint scores for data analysis. However, if the studies assessed the same continuous outcome in different ways, we estimated the treatment effect using the standardised mean difference (SMD) (<a href="./references#CD013531-bbs2-0054" title="CohenJ . Statistical Power Analysis in the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc, 1988.">Cohen 1988</a>). </p> </section> <section id="CD013531-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the participant. For studies comparing more than two intervention groups, we planned to make multiple pair‐wise comparisons between all possible pairs of intervention groups. To avoid double counting, we would divide shared intervention groups evenly amongst the comparisons. For dichotomous outcomes, we planned to divide both the number of events and the total number of participants. For continuous outcomes, we would only divide the total number of participants, and leave the means and standard deviations (SDs) unchanged. We planned to include cross‐over studies for quantitative analysis only if data were separately reported before and after cross‐over, and use only pre‐cross‐over data. We did not anticipate finding any cluster‐RCTs; we would only use study data from such trials if the authors employed appropriate statistical methods in taking the clustering effect into account. We would also exclude cluster‐RCTs in a sensitivity analysis to assess their impact on the results. </p> </section> <section id="CD013531-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors in the case of missing data or studies that did not report data in sufficient detail. We attempted to estimate missing SDs using relevant statistical tools and calculators available in Review Manager 5 if studies reported standard errors (<a href="./references#CD013531-bbs2-0079" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). Studies that failed to report measures of variance were judged as at high risk of reporting bias. </p> </section> <section id="CD013531-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the included studies to determine their homogeneity in terms of participants, intervention, comparator, and outcome. To test for statistical heterogeneity, we employed a Chi² test using a P value of less than 0.1 to give an indication of the presence of heterogeneity. Inconsistency was quantified and represented by the I² statistic. We interpreted the thresholds as follows (<a href="./references#CD013531-bbs2-0065" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2. Cochrane, 2021.">Higgins 2021</a>): </p> <p> <ul id="CD013531-list-0008"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%; may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD013531-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>Most reporting biases were minimised by using an inclusive search strategy. We planned to investigate publication bias using a funnel plot if there were 10 or more studies. The magnitude of publication bias would be determined by visual inspection of the asymmetry of the funnel plot. In addition, we would test funnel plot asymmetry by performing a linear regression of intervention effect estimate against its standard error, weighted by the inverse of the variance of the intervention effect estimate (<a href="./references#CD013531-bbs2-0058" title="EggerM , SmithGD , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315:629. [DOI: 10.1136/bmj.315.7109.629]">Egger 1997</a>). </p> </section> <section id="CD013531-sec-0037"> <h4 class="title">Data synthesis</h4> <p>To summarise the study characteristics, we conducted a narrative synthesis of all the included studies. We then carried out a meta‐analysis if two or more studies assessed similar populations, interventions, and outcomes. We planned to analyse studies of children, adults, and different sub‐intervention types separately. We used Review Manager 5 (<a href="./references#CD013531-bbs2-0079" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We synthesised study data using the random‐effects model if there was statistical heterogeneity (I² &gt; 0%); otherwise, we used the fixed‐effect model. We combined effect estimates of studies that reported data in a similar way in the meta‐analysis. We pooled RRs for dichotomous outcomes, and MDs or SMDs for continuous outcomes, alongside 95% CIs. Where we were unable to carry out a meta‐analysis (e.g. due to lack of uniformity in data reporting), we presented a narrative summary of the included studies. </p> </section> <section id="CD013531-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If we identified heterogeneity, we investigated possible causes and addressed them using the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013531-bbs2-0065" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2. Cochrane, 2021.">Higgins 2021</a>). We planned to undertake subgroup analyses of potential effect modifiers if sufficient data were available. We identified several potential modifiers of effect: </p> <p> <ul id="CD013531-list-0009"> <li> <p>disease activity (active versus inactive disease);</p> </li> <li> <p>pain location;</p> </li> <li> <p>disease location.</p> </li> </ul> </p> </section> <section id="CD013531-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to undertake a sensitivity analysis on the primary outcome of treatment success in order to assess whether the findings of the review were robust to decisions made during the review process. In particular, we planned to exclude studies at high or unclear risk of bias from analyses. Where data analyses included studies with reported and estimated SDs, we excluded studies with estimated SDs to assess whether this affected the findings of the review. We investigated whether the choice of model (fixed‐effect versus random‐effects) affected the results. </p> </section> <section id="CD013531-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We have presented our primary outcomes results in 'Summary of findings' tables. Each comparison and primary outcome was exported to GRADEpro GDT software for quality assessment (<a href="./references#CD013531-bbs2-0062" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 6 December 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2020. Available at gradepro.org.">GRADEpro GDT</a>). Based on risk of bias, inconsistency, imprecision, indirectness, and publication bias, we graded the quality of the evidence for each outcome as high, moderate, low, or very low. These ratings have been defined as follows: </p> <p> <ul id="CD013531-list-0010"> <li> <p>high: further research is very unlikely to change our confidence in the estimate of effect; </p> </li> <li> <p>moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; </p> </li> <li> <p>low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; </p> </li> <li> <p>very low: any estimate of effect is very uncertain.</p> </li> </ul> </p> <p>We justified all decisions to downgrade the quality of studies using footnotes, and made comments to aid the reader's understanding of the review where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013531-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013531-sec-0041"></div> <section id="CD013531-sec-0042"> <h3 class="title">Description of studies</h3> <p>Information on the results of the search, included and excluded studies, and 'Risk of bias' assessment is provided below. </p> <section id="CD013531-sec-0043"> <h4 class="title">Results of the search</h4> <p>We completed our literature search on 29 April 2021 (<a href="./appendices#CD013531-sec-0142">Appendix 1</a>), identifying a total of 3654 records through database searching and 13 additional records from alternative sources. After removal of duplicates, 3282 unique records remained. Title and abstract screening revealed 63 records for full‐text review. After assessing all 63 records, we identified 22 records of 14 studies that met the inclusion criteria and were included in the review. We also identified 9 records of 9 ongoing studies and 24 records of 19 studies awaiting classification. We excluded 8 records of 8 studies for various reasons (see <a href="./references#CD013531-sec-0152" title="">Characteristics of excluded studies</a>). The results of the search are presented in a PRISMA flow diagram (<a href="#CD013531-fig-0001">Figure 1</a>). There are two fully published RCTs (<a href="./references#CD013531-bbs2-0023" title="BaoCH , ZhongJ , LiuHR , GuYP , WuP , GuK , et al. Effect of acupuncture-moxibustion on negative emotions and plasma tryptophan metabolism in patients with Crohn's disease at active stage. Zhongguo Zhen Jiu2021;41(1):17-22. ">Bao 2021</a>; <a href="./references#CD013531-bbs2-0027" title="LeeA , MoultonD , AcraS , WalkerL , MckernanL , RussellA . P039 Clinical hypnosis in pediatric Crohn's Disease: a randomized controlled trial. Gastroenterology2020;158(3):S100-1. LeeA , MoultonD , MckernanL , RussellA , SlaughterJC , Acra S et al. Clinical Hypnosis in Pediatric Crohn's Disease: A Randomized Controlled Pilot Study. Journal of pediatric gastroenterology and nutrition2021;72(3):e63-e70. LeeAD , MoultonDE , MckernanLC , RussellA , AcraS , et al. 1165 Clinical hypnosis in pediatric Crohn's Disease: a randomised controlled trial. Gastroenterology 158;6:S236. ">Lee 2021</a>) which are under awaiting classification and not included in our results and meta‐analyses, as they were identified during our updated search. They will be included in future updated of this review. </p> <div class="figure" id="CD013531-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013531-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013531-sec-0044"> <h4 class="title">Included studies</h4> <section id="CD013531-sec-0045"> <h5 class="title">Setting</h5> <p>Fourteen RCTs involving a total of 743 participants met our inclusion criteria. One study was conducted in China (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>), three in the UK (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>), two in Spain (<a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>), one in the USA (<a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>), two in Turkey (<a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>), one in India (<a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>), one in Israel (<a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>), two in Italy (<a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>), and one in Germany (<a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>). All of the included studies were conducted in hospitals, medical centres, and gastroenterology units, except <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>, which was conducted in an institute of medical science, and three studies for which no information was provided about setting (<a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>). Seven studies were single‐centre (<a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>); five were multicentre (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>); and two studies did not provide this information (<a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>). </p> </section> <section id="CD013531-sec-0046"> <h5 class="title">Participants</h5> <p>All studies reported age in mean (SD), except for two studies that did not report it at all (<a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>); one study that reported mean and range of ages (<a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>); and one study that only mentioned their accepted age range for participants (<a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>). The average age of participants ranged from 31.7, in <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>, to 44.9, in <a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>. The lowest accepted age was 16 years (<a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>), and the highest 80 years (<a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>); 4 studies did not have an upper age limit (<a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>). Four studies did not mention age in their inclusion/exclusion criteria (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>). </p> <p>Five studies examined exclusively CD populations (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>), whilst the remaining studies examined a mix of IBD patients (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>). <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> reported separate CD results. We contacted the authors of the other studies providing mixed IBD results to ask for separate outcome results for their CD participants, and one was able to provide this information (<a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>). </p> <p>Four studies examined participants in an active stage of the disease (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>); six studies participants in an inactive stage of the disease (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>); one study participants in an inactive or mild stage of the disease (<a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>); one study participants in inactive to moderate stages of the disease (<a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>); and one study participants with a mix of inactive and active disease (<a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>). One study did not report on activity of the disease (<a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>). </p> <p>Nine studies reported disease duration (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>). All of these studies presented disease duration in mean (SD) except <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>, which only provided the mean; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>, which reported disease duration in incremental ranges in months; and <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>, which provided the mean and range. Average disease duration ranged from 3 years, in <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>, to 12 years, in <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>. </p> </section> <section id="CD013531-sec-0047"> <h5 class="title">Interventions</h5> <p>The following interventions were assessed in the included trials.</p> <p> <ol id="CD013531-list-0011"> <li> <p>Low FODMAP (fermentable oligo‐, di‐, monosaccharides and polyols) diet versus sham diet (<a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>). </p> </li> <li> <p>Low FODMAP diet versus high FODMAP/normal diet (<a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>). </p> </li> <li> <p>Medicine‐separated moxibustion combined with acupuncture versus wheat bran‐separated moxibustion combined with shallow acupuncture (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>). </p> </li> <li> <p>Mindfulness with cognitive behavioural therapy (CBT) versus no treatment (both groups received standard medical therapy) (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>). </p> </li> <li> <p>Soft non‐manipulative osteopathic versus no treatment besides doctor advice (<a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>). </p> </li> <li> <p>Stress management versus self‐directed stress management (it is unclear whether these interventions replaced standard treatment or were added to standard treatment) versus standard treatment (<a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>). </p> </li> <li> <p>Enteric‐release glyceryl trinitrate versus placebo (<a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>). </p> </li> <li> <p>100 mg olorinab three times per day versus 25 mg olorinab three times per day (<a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>). </p> </li> <li> <p>Relaxation training versus waitlist (<a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>). </p> </li> <li> <p>Web‐based education versus standard book‐based education (<a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>). </p> </li> <li> <p>Yoga intervention versus no treatment (both groups received standard medical therapy) (<a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>). </p> </li> <li> <p>Transcranial direct current stimulation versus sham stimulation (<a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>). </p> </li> <li> <p>Kefir diet (<i>Lactobacillus</i> bacteria) versus no intervention (<a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>). </p> </li> </ol> </p> </section> <section id="CD013531-sec-0048"> <h5 class="title">Outcomes</h5> <p>The length of the interventions ranged from 5 days, in <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>, to 12 months, in <a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>. </p> <section id="CD013531-sec-0049"> <h6 class="title">Primary outcomes</h6> <section id="CD013531-sec-0050"> <p><b>Treatment success as defined by the authors</b></p> <p>Only two studies clearly defined their criteria for treatment success: <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>, which measured pain as a dichotomous outcome (presence or absence of pain), and <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>, which defined success as achieving ≥ 30% reduction in weekly average abdominal pain from baseline to week 8. Treatment success was not explicitly mentioned in the remaining studies. Study authors reported pain as a continuous outcome and did not report numbers of responders for their interventions per any definition. </p> </section> <section id="CD013531-sec-0051"> <p><b>Abdominal pain frequency or change in frequency of pain</b></p> <p>Three studies measured pain frequency. <a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a> evaluated pain frequency using Traditional Chinese Medicine (TCM) symptom scores on an adapted pain intensity scale of 0 to 3: 0 (none), 1 (light), 2 points (moderate), 3 points (severe). The wording of the adapted scale for pain frequency was not mentioned. <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> measured pain frequency in days using the Irritable Bowel Syndrome Severity Scoring System (IBS‐SSS) 0‐to‐100 scoring scale, and in days where pain was reported as moderate or severe using the Gastrointestinal Symptom Rating Scale (GSRS). <a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a> used the total IBS‐SSS scores, which measure frequency and severity of abdominal discomfort, severity of abdominal bloating, satisfaction with bowel habit, and impact of symptoms on life in general. Each domain is scored 0 to 100, and an overall score of 0 to 500 is obtained. A higher score is indicative of more severe symptoms. </p> </section> <section id="CD013531-sec-0052"> <p><b>Abdominal pain intensity or change in pain intensity using any validated scale</b></p> <p>All studies except <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a> measured pain intensity. Five studies used a 0‐to‐100‐millimetre visual analogue scale (VAS), where 0 indicates no pain and 100 (or 10 if measured in centimetres) the worst pain possible (<a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>). One study, <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>, used the 0‐to‐100‐millimetre VAS to separate participants into groups that experienced no pain, pain from 1 to 5, and pain from 6 to 10. Four studies used scoring scales between 0 and 3. <a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a> evaluated pain intensity using TCM symptom scores on a scale of 0 to 3, where 0 = none, 1 = light, 2 = moderate, 3 = severe; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a> used scores that represented the sum of a 7‐day diary card score on a scale of 0 = no pain to 3 = severe pain; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a> used a symptoms diary where participants rated their pain on a scale of 0 to 3, where 0 = none, 1 = mild, 2 = moderate, and 3 = severe; and <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> used the IBS‐SSS 0‐to‐100 scale and the GSRS, which measures severity of pain on a 0‐to‐3 scale. <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a> used a symptom diary where participants rated the severity of their daily pain on a scale of 1 to 3 (1 = mild, 2 = moderate, 3 = severe) and devised their own formulas based on diary card scores to calculate their results. <a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a> used the total IBS‐SSS scores, which measure frequency and severity of abdominal discomfort, severity of abdominal bloating, satisfaction with bowel habit, and impact of symptoms on life in general. Each domain is scored 0 to 100, and an overall score of 0 to 500 is obtained. A higher score is indicative of more severe symptoms. <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a> used a weekly Average Abdominal Pain Score (AAPS), which was the daily pain scores averaged over one week that were larger than 4 on a scale of 0 (no pain) to 10 (worst ever). </p> </section> <section id="CD013531-sec-0053"> <p><b>Withdrawal due to adverse events</b></p> <p>This was reported or could be extracted based on the text in 10 studies (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>). </p> </section> </section> <section id="CD013531-sec-0054"> <h6 class="title">Secondary outcomes</h6> <section id="CD013531-sec-0055"> <p><b>Anxiety/depression</b></p> <p>Five studies mentioned having measured anxiety or depression, or both (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>). Two of these studies used the Hospital Anxiety and Depression Scale (HADS) (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>); however, <a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a> only reported baseline scores, and <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a> did not report any scores. <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a> used Spielberger’s State‐Trait Anxiety Inventory to measure anxiety and the 0‐to‐10‐centimetre VAS to measure depression; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a> also used Spielberger’s State‐Trait Anxiety Inventory to measure anxiety. <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a> used the Beck Depression Inventory to measure depression, but only reported baseline scores. </p> </section> <section id="CD013531-sec-0056"> <p><b>Adverse events (total number of participants with any event)</b></p> <p>Six studies reported the total number of participants with adverse events (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>). <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a> reported total occurrences of adverse events, but not the number of participants with adverse events. </p> </section> <section id="CD013531-sec-0057"> <p><b>Serious adverse events (as defined by the authors within the primary study )</b></p> <p>The same six studies that reported numbers of participants with adverse events also reported numbers of participants with serious adverse events (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>). </p> </section> </section> </section> <section id="CD013531-sec-0058"> <h5 class="title">Funding sources and conflicts of interest</h5> <p>Eight studies reported their sources of funding (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>). Three studies were funded via government grants (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>), two by private foundations (<a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>), one by an industrial partner (<a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>), and two studies reported having received no funding (<a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>). </p> <p>Eight studies made declarations on conflicts of interest (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>). Six studies declared no conflicts of interest (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>); one study declared industry connections and ownership of an invention connected to their intervention (<a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>); and one study declared that one of the authors is an employee of the industrial partner that provided funding (<a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>). </p> </section> </section> <section id="CD013531-sec-0059"> <h4 class="title">Excluded studies</h4> <p>We excluded eight studies for various reasons. The reasons for exclusion of each study are presented in the <a href="./references#CD013531-sec-0152" title="">Characteristics of excluded studies</a> table and are summarised below. </p> <p> <ul id="CD013531-list-0012"> <li> <p>Wrong outcomes (3 studies) (<a href="./references#CD013531-bbs2-0015" title="ACTRN12617000876392. IBD mindfulness - mindfulness for youth with Inflammatory Bowel Disease (IBD) and depression trial [A pilot randomised-controlled trial (RCT) of mindfulness-based cognitive therapy (MBCT) for youth with Inflammatory Bowel Disease (IBD) and Depression]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373115&amp;isReview=true (first received 12 June 2017). ">ACTRN12617000876392</a>; <a href="./references#CD013531-bbs2-0016" title="EngelMA , StrackeB . Improvement of health-related quality of life in patients with chronic inflammatory bowel disease after 4 weeks of additive treatment with menthacarin - a randomized, placebo-controlled trial. United European Gastroenterology Journal2016;4(5):A618. ">Engel 2016</a>; <a href="./references#CD013531-bbs2-0022" title="TrippDA , VerreaultP , GatesJ , RopeleskiM , BeyakM . Development and piloting of a cognitive-behavioral self management program for patients with inflammatory bowel disease: an early stage update. Gastroenterology2017;152(5):S799. ">Tripp 2017</a>). </p> </li> <li> <p>Wrong interventions (2 studies) (<a href="./references#CD013531-bbs2-0017" title="ForbesL . Online Mindfulness Intervention for Inflammatory Bowel Disease Patients: Adherence and Efficacy. Charlotte (NC): The University of North Carolina, 2018. ">Forbes 2019</a>; <a href="./references#CD013531-bbs2-0018" title="GearryRB , IrvingPM , BarrettJS , NathanDM , ShepherdSJ , GibsonPR . Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease - a pilot study. Journal of Crohn's &amp; Colitis2009;3(1):8-14. ">Gearry 2009</a>). </p> </li> <li> <p>Not RCTs (2 studies) (<a href="./references#CD013531-bbs2-0020" title="McCormickM , Reed-KnightB , LewisJD , GoldBD , BlountRL . Coping skills for reducing pain and somatic symptoms in adolescents with IBD. Inflammatory Bowel Diseases2010;16(12):2148-57. ">McCormick 2010</a>; <a href="./references#CD013531-bbs2-0021" title="SpagnuoloR , CoscoC , MancinaRM , RuggieroG , GarieriP , CoscoV , et al. Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome. European Review for Medical and Pharmacological Sciences2017;21(Suppl 2):102-7. SpagnuoloR , RuggieroG , CoscoC , CoscoV , GarieriP , GidaroA , et al. Beta-glucan, inositol and digestive enzymes in patients with inflammatory bowel disease associated with irritable bowel syndrome. Digestive and Liver Disease2016;48 (Suppl):e162. ">Spagnuolo 2017</a>). </p> </li> <li> <p>Wrong indication (1 study) (<a href="./references#CD013531-bbs2-0019" title="ISRCTN98226923. Fermentable dietary carbohydrates as triggers of functional gut symptoms in patients with inflammatory bowel disease. www.isrctn.com/ISRCTN98226923 (first received 20 January 2014). ">ISRCTN98226923</a>). </p> </li> </ul> </p> </section> </section> <section id="CD013531-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>The results of our ‘Risk of bias’ assessment are presented below (<a href="#CD013531-fig-0002">Figure 2</a>; <a href="#CD013531-fig-0003">Figure 3</a>). Further details can be found in the ‘Risk of bias’ tables in the <a href="./references#CD013531-sec-0151" title="">Characteristics of included studies</a> tables. </p> <div class="figure" id="CD013531-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013531-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013531-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013531-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013531-sec-0061"> <h4 class="title">Allocation</h4> <p>Randomisation was described clearly in nine studies, which we rated as at low risk of bias (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>), and insufficiently described in five studies, which were assessed as at unclear risk of bias (<a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>). </p> <p>Four studies were assessed as at low risk of allocation concealment bias (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>), as allocation concealment was judged to be adequately described. We rated the other 10 studies as at unclear risk of bias for allocation concealment (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>), as they provided insufficient or no information. </p> </section> <section id="CD013531-sec-0062"> <h4 class="title">Blinding</h4> <p>We rated two studies as having a low risk of performance bias since they used as control a placebo that was identical to the intervention product, <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>, or a sham procedure that could not be differentiated from the intervention, <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>. We rated <a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a> as at unclear risk of performance bias as there was no information about blinding, and we received no response to our enquiries to the author. We assessed the other 11 studies as at high risk of performance bias, as neither participants nor study personnel were blinded to the interventions, or the studies were open‐label (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>); however, <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> used a sham diet to blind their participants to the intervention, which is not typical in diet RCTs due to the difficulty it entails. </p> <p>Five studies provided sufficient information about blinding of outcome assessment and were assessed as at low risk of detection bias (<a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>). The remaining nine studies provided insufficient information for judgement and were judged to be at unclear risk of detection bias (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>). </p> </section> <section id="CD013531-sec-0063"> <h4 class="title">Incomplete outcome data</h4> <p>Ten studies provided sufficient information for judgement and were assessed as at low risk of attrition bias (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>). We assessed three studies as at unclear risk of bias for this domain (<a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>), and one study as at high risk of attrition bias (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>). </p> </section> <section id="CD013531-sec-0064"> <h4 class="title">Selective reporting</h4> <p>Nine studies reported all outcomes they set out to assess and were judged to be at low risk of reporting bias (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>). Four studies provided insufficient information in the reports or protocols to permit a judgement as to whether all outcomes had been reported; these studies were assessed as at unclear risk of reporting bias (<a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>). We rated the remaining study as at high risk of bias for this domain (<a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>). </p> </section> <section id="CD013531-sec-0065"> <h4 class="title">Other potential sources of bias</h4> <p>We rated eight studies as at low risk of other potential sources of bias (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>). We assessed two studies as at unclear risk of bias for this domain, as there were imbalances in the baseline characteristics of participants, and it is unclear how this may have influenced the results (<a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>). We rated four studies as having a high risk of other bias for the following reasons: significant differences in the baseline characteristics of participants that were highly likely to have affected the results (<a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>); the study declared that one or more authors were directly employed by the pharmaceutical companies funding the study (<a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>); bias was detected in the way the efficacy of the studied intervention was presented in their introduction (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>). </p> </section> </section> <section id="CD013531-sec-0066"> <h3 class="title" id="CD013531-sec-0066">Effects of interventions</h3> <p>See: <a href="./full#CD013531-tbl-0001"><b>Summary of findings 1</b> Low FODMAP diet compared to sham diet for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</a>; <a href="./full#CD013531-tbl-0002"><b>Summary of findings 2</b> Medicine‐separated moxibustion combined with acupuncture compared with wheat bran‐separated moxibustion combined with shallow acupuncture for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</a>; <a href="./full#CD013531-tbl-0003"><b>Summary of findings 3</b> Mindfulness with cognitive behavioural therapy (CBT) compared with no treatment (both groups received standard medical therapy) for the management of abdominal pain in Crohn's Disease and inflammatory bowel disease</a>; <a href="./full#CD013531-tbl-0004"><b>Summary of findings 4</b> soft non‐manipulative osteopathic treatment compared to no intervention for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</a>; <a href="./full#CD013531-tbl-0005"><b>Summary of findings 5</b> Directed stress management (it is unclear whether these interventions replaced standard treatment or were added to standard treatment) versus standard treatment for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</a>; <a href="./full#CD013531-tbl-0006"><b>Summary of findings 6</b> Self‐directed stress management (it is unclear whether these interventions replaced standard treatment or were added to standard treatment) versus standard treatment for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</a>; <a href="./full#CD013531-tbl-0007"><b>Summary of findings 7</b> Enteric‐release glyceryl trinitrate compared to placebo for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</a>; <a href="./full#CD013531-tbl-0008"><b>Summary of findings 8</b> 100 mg olorinab 3 times/day compared to 25 mg olorinab 3 times/day for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</a>; <a href="./full#CD013531-tbl-0009"><b>Summary of findings 9</b> Relaxation training compared to waitlist for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</a>; <a href="./full#CD013531-tbl-0010"><b>Summary of findings 10</b> Web‐based education compared to standard book‐based education for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</a>; <a href="./full#CD013531-tbl-0011"><b>Summary of findings 11</b> Yoga intervention compared to no treatment (both groups received standard medical therapy) for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</a>; <a href="./full#CD013531-tbl-0012"><b>Summary of findings 12</b> Transcranial direct current stimulation compared to sham stimulation for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</a>; <a href="./full#CD013531-tbl-0013"><b>Summary of findings 13</b> Kefir ( <i>Lactobacillus</i> bacteria) compared to no intervention for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</a> </p> <p>A summary of the interventions and key outcome definitions and data are presented in <a href="#CD013531-tbl-0014">Table 1</a> and <a href="#CD013531-tbl-0015">Table 2</a> and explained below. </p> <div class="table" id="CD013531-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Primary outcome details</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Disease type</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Disease activity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Length of intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Measurement of pain</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of randomised participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low FODMAP diet vs sham diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD/IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain frequency and intensity:</p> <p>IBS‐SSS for pain rating scale 0 to 100,</p> <p>GSRS rating scale 0 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> <p>(IG: 27; CG: 25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low FODMAP diet vs sham diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>VAS rating scale 0 to 10 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(IG: 10; CG: 20)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low FODMAP diet vs high FODMAP/normal diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks cross‐over (4 weeks x 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>VAS rating scale 0 to 10 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> <p>(IG: 25; CG: 25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medicine‐separated moxibustion combined with acupuncture vs wheat bran‐separated moxibustion combined with shallow acupuncture </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain frequency and intensity:</p> <p>Traditional Chinese Medicine rating scale 0 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> <p>(IG: 51; CG: 51)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mindfulness with CBT + standard medical therapy vs standard medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain frequency and severity of abdominal discomfort, severity of abdominal bloating, satisfaction with bowel habit, and impact of symptoms on life in general. Each domain is scored 0 to 100, and an overall score of 0 to 500 is obtained. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> <p>(IG: 33; CG: 33)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Soft non‐manipulative osteopathic vs no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>VAS rating scale 0 to 10 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(IG: 16; CG: 14)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stress management vs self‐directed stress management vs standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>rating scale 1 to 3 and author formulas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(IG1: 15; IG2: 15; CG: 15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric‐release glyceryl trinitrate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>rating scale 0 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> <p>(IG: 34; CG: 36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg olorinab 3 times/day vs 25 mg olorinab 3 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive to mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>AAPS of 0‐to‐10 Likert scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> <p>(IG: 8; CG: 6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relaxation training vs waitlist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>VAS rating scale 0 to 10 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> <p>(IG: 28; CG: 28)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based education vs standard book‐based education</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mix of active and inactive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>VAS rating scale 0 to 10 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> <p>(IG: 10; CG: 10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yoga intervention + standard medical therapy vs standard medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence or absence of pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> <p>(IG: 50; CG: 50)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transcranial direct current stimulation vs sham stimulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>Pressure Pain Threshold taken with algometer,</p> <p>VAS rating scale 0 to 10 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> <p>(IG: 10; CG: 10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kefir diet (<i>Lactobacillus</i> bacteria) vs no intervention </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD/IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>rating scale 0 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> <p>(IG: 28; CG: 20)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AAPS: average abdominal pain score</p> <p>CBT: cognitive behavioural therapy</p> <p>CD: Crohn's disease</p> <p>CG: control group</p> <p>FODMAP: fermentable oligo‐, di‐, monosaccharides and polyols</p> <p>IG: intervention group</p> <p>GSRS: Gastrointestinal Symptom Rating Scale</p> <p>IBD: inflammatory bowel disease</p> <p>IBS‐SSS: Irritable Bowel Syndrome Severity Scoring System</p> <p>VAS: visual analogue scale</p> </div> </div> <div class="table" id="CD013531-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Primary outcome data</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment success end of study data IG/CG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain frequency end of study data IG/CG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain intenstiy end of study data IG/CG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events IG/CG</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low FODMAP diet vs sham diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IBS‐SSS all participants  mean(SD)</p> <p>IG= 36(26); CG= 38(25)</p> <p> </p> <p>IBS‐SSS CD mean (SD)</p> <p>IG = 36(138.4); CG=48(128.2)</p> <p> </p> <p>GSRS all participants mean(SD) </p> <p>IG= 1.5(1.6); CG= 1.1(1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IBS‐SSS all participants  mean(SD)</p> <p>IG=22(15.6) ; CG=30(15)</p> <p> </p> <p>IBS‐SSS CD mean (SD)</p> <p>IG = 24(82.3); CG= 32(69.3)</p> <p> </p> <p>GSRS all participants mean(SD) </p> <p>IG=0.9(2.6) ; CG= 0.7(22.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG: 2</p> <p>CG: 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low FODMAP diet vs sham diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean(SD): IG=3.3 (1.9)</p> <p>CG= 4.3(2.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low FODMAP diet vs high FODMAP/normal diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean(SD): IG=1.1(1.6)</p> <p>CG=3.1(2.3)</p> <p>(unclear if average of both cross‐over arms or from the first or second phase of the cross‐over) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medicine‐separated moxibustion combined with acupuncture vs wheat bran‐separated moxibustion combined with shallow acupuncture </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean (no SD provided)</p> <p>IG=0</p> <p>CG=0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean (no SD provided)</p> <p>IG=2</p> <p>CG=1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=0</p> <p>CG=0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mindfulness with CBT + standard medical therapy vs standard medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Frequency and intensity measured together as part of the IBS‐SSS score mean(SD)</p> <p>IG= 187 (97)</p> <p>CG= 224 (111)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=0</p> <p>CG=0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Soft non‐manipulative osteopathic vs no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean(SD): IG=2.72(2.66)</p> <p>CG=2.71(2.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=0</p> <p>CG=0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stress management vs self‐directed stress management vs standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean(SD): IG=13.3(28)</p> <p>CG=47.6(47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric‐release glyceryl trinitrate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean(no SD presented)</p> <p>IG=8.1</p> <p>CG=8.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=9</p> <p>CG=3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg olorinab 3 times/day vs 25 mg olorinab 3 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ≥ 30% reduction in weekly AAPS</p> <p>IG: 5 </p> <p>CG: 6 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 hours postdose mean(SD could not be calculated from figure)</p> <p>IG=1.9</p> <p>CG= 1.9</p> <p> </p> <p>Mean change in AAPS (no SD)</p> <p>IG= ‐4.6</p> <p>CG= ‐4.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=0</p> <p>CG=0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relaxation training vs waitlist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean(SD): IG= 2.23(1.83)</p> <p>CG= 2.95(2.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based education vs standard book‐based education</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean(SD): IG= 1.8(2.04)</p> <p>CG= 1.93(2.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=0</p> <p>CG=0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yoga intervention + standard medical therapy vs standard medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=0</p> <p>CG=0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transcranial direct current stimulation vs sham stimulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean(SD): IG= 2.8(2.3)</p> <p>CG= 4.45(1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=0</p> <p>CG=0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kefir diet (<i>Lactobacillus</i> bacteria) vs no intervention </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CD pain intensity mean(SD)</p> <p>IG= 0.2(0.63)</p> <p>CG= 1.3(0.67)</p> <p> </p> <p>IBD pain intensity mean(SD)</p> <p>IG= 0.9(0.97)</p> <p>CG= 0.28(0.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=0</p> <p>CG=0</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AAPS: average abdominal pain score</p> <p>CBT: cognitive behavioural therapy</p> <p>CD: Crohn's disease</p> <p>CG: control group</p> <p>FODMAP: fermentable oligo‐, di‐, monosaccharides and polyols</p> <p>IG: intervention group</p> <p>GSRS: Gastrointestinal Symptom Rating Scale</p> <p>IBD: inflammatory bowel disease</p> <p>IBS‐SSS: Irritable Bowel Syndrome Severity Scoring System</p> <p>VAS: visual analogue scale</p> </div> </div> <section id="CD013531-sec-0067"> <h4 class="title">Low FODMAP diet versus sham diet</h4> <p>Two studies compared a diet low in FODMAP to a sham diet (<a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>). Both studies included participants with either CD or UC and who were at an inactive stage of their disease. <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a> (n = 30) included participants with a Crohn's Disease Activity Index (CDAI) score &lt; 150 for CD and a full Mayo score &lt; 3 for UC, whilst in <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> (n = 52) quiescent IBD was defined by all of the following: physician global assessment, stable medications, no IBD flare in the previous six months, faecal calprotectin &lt; 250 mg/g, and serum C‐reactive protein (CRP) &lt; 10 mg/L. The length of the intervention was four weeks in <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> and six to eight weeks in <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>. </p> <section id="CD013531-sec-0068"> <h5 class="title">Primary outcomes</h5> <p>Treatment success was not reported. Pain in <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> was measured using the pain subscale of the IBS‐SSS that rates pain on a scale of 0 to 100 and the GSRS pain‐rating scale of 0 to 3, whilst <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a> used the 0‐to‐100‐millimetre VAS. </p> <section id="CD013531-sec-0069"> <h6 class="title">Pain frequency</h6> <p>Only <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> measured pain frequency. </p> <p>At the end of study, the mean (SD) IBS‐SSS pain frequency in days was 36 (26) days for the 27 CD and UC participants in the low FODMAP group, and 38 (25) days for the 25 participants in the sham diet group. There was no clear difference in days of pain for CD and UC participants when a low FODMAP diet was compared to a sham diet in <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> (mean difference (MD) −2.00, 95% confidence interval (CI) −15.86 to 11.86). The certainty of evidence was very low due to unclear risk of bias and imprecision (<a href="./references#CD013531-fig-0004" title="">Analysis 1.1</a>; <a href="./full#CD013531-tbl-0001">summary of findings Table 1</a>). </p> <p>The mean (SD) days in which pain was rated as moderate or severe on the GSRS during the final week of the diet was 1.5 (1.6) for the low FODMAP group and 1.1 (1.5) for the sham diet group. There was no clear difference in days of pain during the last week of the diet for CD and UC participants when a low FODMAP diet was compared to a sham diet in <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> (MD 0.40, 95% CI −0.44 to 1.24). The certainty of evidence was very low due to unclear risk of bias and imprecision (<a href="./references#CD013531-fig-0005" title="">Analysis 1.2</a>; <a href="./full#CD013531-tbl-0001">summary of findings Table 1</a>). </p> <p><a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> also provided separate data for their CD participants. At end of study, the mean (SD) IBS‐SSS pain frequency in days was 36 (138.4) days for the 14 CD participants in the low FODMAP group, and 48 (128.2) days for the 12 participants in the sham diet group. There was no clear difference in days of pain for CD participants when a low FODMAP diet was compared to a sham diet in <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> (MD −12.00, 95% CI −114.55 to 90.55). The certainty of evidence was very low due to unclear risk of bias and imprecision (<a href="./references#CD013531-fig-0006" title="">Analysis 1.3</a>; <a href="./full#CD013531-tbl-0001">summary of findings Table 1</a>). </p> <p>We requested separate CD data for the GSRS but were not able to obtain this information from the authors. </p> </section> <section id="CD013531-sec-0070"> <h6 class="title">Pain intensity</h6> <p>Both studies measured pain intensity, in <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> on a 0‐to‐100mm VAS and in <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a> on a 0‐to‐10cm VAS. To combine them for analysis we multiplied the <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a> results by 10. </p> <p>When the effects of both studies were analysed together, there was a small difference in intensity of pain for CD and UC participants (MD −8.46, 95% CI −15.76 to −1.16). The certainty of evidence was very low due to high risk of bias and imprecision, so no conclusions could be drawn (<a href="./references#CD013531-fig-0007" title="">Analysis 1.4</a>; <a href="./full#CD013531-tbl-0001">summary of findings Table 1</a>). </p> <p>In <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>, the mean (SD) pain intensity on the GSRS was 0.9 (2.6) for the low FODMAP group and 0.7 (22.5) for the sham diet group. There was no clear difference in pain intensity for CD and UC participants when a low FODMAP diet was compared to a sham diet on a 4‐point scale in <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> (MD 0.20, 95% CI −8.67 to 9.07). The certainty of evidence was very low due to unclear risk of bias and imprecision (<a href="./references#CD013531-fig-0008" title="">Analysis 1.5</a>; <a href="./full#CD013531-tbl-0001">summary of findings Table 1</a>). </p> <p><a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> also provided separate data for their CD participants. At the end of study, the mean (SD) IBS‐SSS pain intensity was 24 (82.3) for the 14 CD participants in the low FODMAP group and 32 (69.3) for the 12 CD participants in the sham diet group. There was no clear difference in intensity of pain for CD participants when a low FODMAP diet was compared to a sham diet in <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> (MD −8.00, 95% CI −66.27 to 50.27). The certainty of evidence was very low due to unclear risk of bias and imprecision (<a href="./references#CD013531-fig-0009" title="">Analysis 1.6</a>; <a href="./full#CD013531-tbl-0001">summary of findings Table 1</a>). </p> <p>We requested separate CD data for the GSRS but were not able to obtain this information from the authors. </p> </section> <section id="CD013531-sec-0071"> <h6 class="title">Withdrawals due to adverse events</h6> <p>Only <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> reported withdrawals due to adverse events. There were two withdrawals due to adverse events in the low FODMAP group (one IBD relapse, one commencement of antibiotics) and one in the sham diet group (one IBD relapse). There was no clear difference in the effect of the intervention on withdrawals due to adverse events (risk ratio (RR) 1.85, 95% CI 0.18 to 19.19) (<a href="./references#CD013531-fig-0010" title="">Analysis 1.7</a>; <a href="./full#CD013531-tbl-0001">summary of findings Table 1</a>). The certainty of the evidence was very low due to risk of bias and imprecision. We requested data from <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a> but were unable to obtain this information. </p> </section> </section> <section id="CD013531-sec-0072"> <h5 class="title">Secondary outcomes</h5> <p>Neither <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> nor <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a> reported on anxiety/depression. Only <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> reported adverse events and serious adverse events. There were no serious adverse events, and adverse events were reported in six participants in total. Three of these were the ones mentioned above in withdrawals due to adverse events. The other three were one case of worsening of abdominal pain (sham diet group), and two cases of flu‐like symptoms and sinusitis (one in each group). </p> <p>One participant each in the intervention and control groups reported flu‐like symptoms and sinusitis, and one participant in the intervention group reported worsening of abdominal pain. One participant each in the intervention and control groups reported IBD relapse. </p> </section> </section> <section id="CD013531-sec-0073"> <h4 class="title">Low FODMAP diet versus high FODMAP/normal diet</h4> <p>One study (n = 50) compared a diet low in FODMAP to a high FODMAP/normal diet (<a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>). The study included participants with either CD or UC who were at an inactive stage of their disease. Study participants had normal inflammatory parameters (CRP, white blood cells) and were deemed to be in clinical remission (CDAI &lt; 150 for CD and a full Mayo &lt; 2 for UC) but had residual abdominal symptoms (abdominal pain, diarrhoea, bloating). The length of the intervention was eight weeks; the study had a cross‐over design whereby groups alternated interventions after four weeks. We wrote to the authors for pre‐cross‐over data but received no response. </p> <section id="CD013531-sec-0074"> <h5 class="title">Primary outcomes</h5> <p>Treatment success was not reported. <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a> measured pain using the 0‐to‐10‐centimetre VAS. Pain frequency and withdrawals due to adverse events were not reported. </p> <section id="CD013531-sec-0075"> <h6 class="title">Pain intensity</h6> <p><a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a> reported that at the end of study the mean (SD) pain score was 1.1 (1.6) in the low FODMAP diet group and 3.1 (2.3) in the high FODMAP/normal diet group. However, it is unclear whether these scores were averages of both cross‐over arms, or if they were from the first or second phase of the cross‐over. The cross‐over design of the study precluded any analyses of the results. </p> </section> </section> <section id="CD013531-sec-0076"> <h5 class="title">Secondary outcomes</h5> <p><a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a> did not report on anxiety/depression, serious adverse events, or total number of participants with any event. </p> </section> </section> <section id="CD013531-sec-0077"> <h4 class="title">Medicine‐separated moxibustion combined with acupuncture versus wheat bran‐separated moxibustion combined with shallow acupuncture </h4> <p>One study (n = 102) compared medicine‐separated moxibustion combined with acupuncture to wheat bran‐separated moxibustion combined with shallow acupuncture (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>). The study included only CD participants who were at a mild to moderate stage of the disease (defined as a CDAI between 151 and 350). The length of the intervention was 12 weeks. </p> <section id="CD013531-sec-0078"> <h5 class="title">Primary outcomes</h5> <p><a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a> did not report on treatment success. Pain was measured on the TCM 4‐point rating scale from 0 to 3. </p> <section id="CD013531-sec-0079"> <h6 class="title">Pain frequency</h6> <p>Pain frequency was reduced from an average score of 3 at baseline to 0 at end of study in the medicine‐separated moxibustion group, and from an average score of 1 to 0 in the wheat bran‐separated moxibustion group. The authors did not provide SD values, so we could not conduct any analyses of the results; we requested this information but received no response. It is uncertain whether medicine‐separated moxibustion combined with acupuncture leads to a difference in average pain frequency when compared with wheat bran‐separated moxibustion combined with shallow acupuncture. </p> </section> <section id="CD013531-sec-0080"> <h6 class="title">Pain intensity</h6> <p>Pain intensity was reduced from an average score of 3 at baseline to 2 at end of study in the medicine‐separated moxibustion group, and remained at an average score of 1 for the wheat bran‐separated moxibustion group. The authors did not provide SD values, so we could not conduct any analyses of the results; we requested this information but received no response. It is uncertain whether medicine‐separated moxibustion combined with acupuncture leads to a difference in average pain intensity when compared with wheat bran‐separated moxibustion combined with shallow acupuncture. </p> </section> <section id="CD013531-sec-0081"> <h6 class="title">Withdrawals due to adverse events</h6> <p>There were no withdrawals due to adverse events in either the medicine‐separated moxibustion or wheat bran‐separated moxibustion group, so there was no estimable relative effect of the intervention on withdrawals due to adverse events (<a href="./references#CD013531-fig-0011" title="">Analysis 2.1</a>; <a href="./full#CD013531-tbl-0002">summary of findings Table 2</a>). </p> </section> </section> <section id="CD013531-sec-0082"> <h5 class="title">Secondary outcomes</h5> <p>The authors reported that there were no serious adverse events. Two participants experienced any adverse event, one in each treatment group. Anxiety or depression was not reported. </p> </section> </section> <section id="CD013531-sec-0083"> <h4 class="title">Mindfulness with cognitive behavioural therapy (CBT) versus no treatment (both groups received standard medical therapy) </h4> <p>One study (n = 66) compared mindfulness with CBT to no treatment (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>). The study included participants with CD or UC who were at an inactive stage of their disease. Study participants had a diagnosis of UC or CD that was in remission based on a clinical activity index score and a CRP level &lt; 10 mg/L. The length of the intervention was 12 months. </p> <section id="CD013531-sec-0084"> <h5 class="title">Primary outcomes</h5> <p><a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a> did not report on treatment success. Pain was measured on the 0‐to‐500 IBS‐SSS, which is the sum of five separate 0‐to‐100 scales that measure five different pain‐related symptoms: pain frequency and severity of abdominal discomfort, severity of abdominal bloating, satisfaction with bowel habit, and impact of symptoms on life in general. </p> <section id="CD013531-sec-0085"> <h6 class="title">Pain frequency and intensity</h6> <p>At the end of the study, mean (SD) IBS‐SSS score (which includes pain frequency and severity) was 187 (97) for the mindfulness with CBT group and 224 (111) for the no‐treatment group. There was no clear difference in IBS‐SSS symptoms between groups (MD −37.00, 95% CI −87.29 to 13.29). The certainty of evidence was very low due to unclear risk of bias and imprecision (<a href="./references#CD013531-fig-0012" title="">Analysis 3.1</a>; <a href="./full#CD013531-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD013531-sec-0086"> <h6 class="title">Withdrawals due to adverse events</h6> <p>There were no withdrawals due to adverse events in either group, so there was no estimable relative effect of the intervention on withdrawals due to adverse events (<a href="./references#CD013531-fig-0013" title="">Analysis 3.2</a>; <a href="./full#CD013531-tbl-0003">summary of findings Table 3</a>). </p> </section> </section> <section id="CD013531-sec-0087"> <h5 class="title">Secondary outcomes</h5> <p>Anxiety and depression at the end of study were not presented. Serious adverse events or total number of participants with any adverse event was not reported. </p> </section> </section> <section id="CD013531-sec-0088"> <h4 class="title">Soft non‐manipulative osteopathic versus no intervention</h4> <p>One study (n = 30) compared soft non‐manipulative osteopathic treatment to no intervention (<a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>). The study included only CD participants, and it was unclear whether participants had active or inactive stage of the disease. The length of the intervention was 30 days. </p> <section id="CD013531-sec-0089"> <h5 class="title">Primary outcomes</h5> <p><a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a> did not report on treatment success. Pain was measured on the 0‐to‐10‐centimetre VAS. Pain frequency was not measured. </p> <section id="CD013531-sec-0090"> <h6 class="title">Pain intensity</h6> <p>The mean (SD) score at end of the study was 2.72 (2.66) for the osteopathic group and 2.71 (2.43) for the no‐intervention group. There was no clear difference in pain intensity in the osteopathic group when compared to the no‐intervention group (MD 0.01, 95% CI −1.81 to 1.83). The certainty of evidence was very low due to high risk of bias and imprecision (<a href="./references#CD013531-fig-0014" title="">Analysis 4.1</a>; <a href="./full#CD013531-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD013531-sec-0091"> <h6 class="title">Withdrawals due to adverse events</h6> <p>There were no withdrawals due to adverse events in either group, so there was no estimable relative effect of the intervention on withdrawals due to adverse events (<a href="./references#CD013531-fig-0015" title="">Analysis 4.2</a>; <a href="./full#CD013531-tbl-0004">summary of findings Table 4</a>). </p> </section> </section> <section id="CD013531-sec-0092"> <h5 class="title">Secondary outcomes</h5> <p>The authors reported that no adverse events occurred in this study. Anxiety/depression results were not reported. </p> </section> </section> <section id="CD013531-sec-0093"> <h4 class="title">Directed stress management versus self‐directed stress management (it is unclear whether these interventions replaced standard treatment or were added to standard treatment) versus standard treatment </h4> <p>One study (n = 45) compared directed stress management to standard treatment and self‐directed management to standard treatment (<a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>). It was unclear whether the interventional treatments included standard treatment or not. We attempted to contact the author but received no response. </p> <p>The study included only CD participants who were at an inactive stage of the disease based on the Harvey‐Bradshaw Index. The length of the intervention was eight weeks. </p> <section id="CD013531-sec-0094"> <h5 class="title">Primary outcomes</h5> <p><a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a> did not report on treatment success. Pain scores were calculated with author‐derived formulas that were based on a 3‐point rating scale from 1 to 3. Pain frequency and withdrawals due to adverse events were not reported in this study. </p> <section id="CD013531-sec-0095"> <h6 class="title">Pain intensity</h6> <p>At end of the study the mean (SD) pain score was 13.3 (28.8) for the directed stress management group; 17.1 (29) for the self‐directed stress management group; and 47.6 (47) for the standard treatment group. There was a difference in the directed stress management group when compared to the standard treatment group ( MD ‐34.30, 95% CI ‐61.99 to ‐6.61 ) and in the self‐directed stress management group when compared to the standard treatment group ( MD ‐30.50, 95% CI ‐58.45 to ‐2.55 ). The certainty of evidence was very low due to high risk of bias and imprecision, therefore no conclusions could be drawn (<a href="./references#CD013531-fig-0016" title="">Analysis 5.1</a>; <a href="./references#CD013531-fig-0017" title="">Analysis 6.1</a> <a href="./full#CD013531-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD013531-tbl-0006">summary of findings Table 6</a>). </p> </section> </section> <section id="CD013531-sec-0096"> <h5 class="title">Secondary outcomes</h5> <p><a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a> did not report anxiety/depression, serious adverse events, or total number of participants with any adverse event. </p> </section> </section> <section id="CD013531-sec-0097"> <h4 class="title">Enteric‐release glyceryl trinitrate versus placebo</h4> <p>One study (n = 70) compared enteric‐release glyceryl trinitrate to placebo (<a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>). The study included only CD participants at a moderate to severe stage of the disease with a CDAI of between 150 and 450. The length of the intervention was 12 weeks. </p> <section id="CD013531-sec-0098"> <h5 class="title">Primary outcomes</h5> <p><a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a> did not report on treatment success. Pain was measured on a 4‐point scale from 0 to 3. Pain frequency was not reported in this study. </p> <section id="CD013531-sec-0099"> <h6 class="title">Pain intensity</h6> <p>At end of study the mean score was 8.1 for the glyceryl group and 8.6 for the placebo group. No analyses could be conducted with these results as SD values were unobtainable from the authors. It is uncertain whether enteric‐release glyceryl trinitrate leads to any differences in pain intensity compared to placebo. </p> </section> <section id="CD013531-sec-0100"> <h6 class="title">Withdrawal due to adverse events</h6> <p>Nine participants in the glyceryl group (headache = 1, worsening clinical condition = 4, generalised rash = 1, mood change/irritability = 1, loss of consciousness/memory = 1) and three participants in the placebo group (headache = 2, worsening clinical condition = 1) experienced adverse events that led to withdrawal from the study. There was no clear difference in withdrawals due to adverse events when enteric‐release glyceryl trinitrate was compared to placebo (RR 3.18, 95% CI 0.94 to 10.76). The certainty of the evidence was very low due to unclear risk of bias and high imprecision (<a href="./references#CD013531-fig-0018" title="">Analysis 7.1</a>; <a href="./full#CD013531-tbl-0007">summary of findings Table 7</a>). </p> </section> </section> <section id="CD013531-sec-0101"> <h5 class="title">Secondary outcomes</h5> <p>The authors of <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a> reported that there were no serious adverse events in either group. Nineteen participants in the enteric‐release glyceryl trinitrate group and 13 participants in the placebo group experienced any adverse event. Anxiety/depression was not measured in this study. </p> </section> </section> <section id="CD013531-sec-0102"> <h4 class="title">100 mg olorinab three times/day versus 25 mg olorinab three times/day</h4> <p>One study (n = 14) compared 100 mg olorinab taken three times per day to 25 mg olorinab taken three times per day (<a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>). The study only included CD participants who were at an inactive or mild stage of the disease with a simple endoscopic score CD &lt; 10 or faecal calprotectin &lt; 500 μg/g. The length of the intervention was eight weeks. </p> <section id="CD013531-sec-0103"> <h5 class="title">Primary outcomes</h5> <p>Treatment success in <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a> was defined as a ≥ 30% reduction in weekly Average Abdominal Pain Score (AAPS) from baseline to week 8, as measured on a 0‐to‐10 Likert scale. Pain frequency was not measured in this study. </p> <section id="CD013531-sec-0104"> <h6 class="title">Pain intensity</h6> <p>At end of study, five of eight participants had achieved a 30% reduction in weekly AAPS in the 100 mg olorinab group, whilst six of six participants had achieved a 30% reduction in the 25 mg olorinab group. There was no clear difference in pain intensity between groups (RR 0.66, 95% CI 0.38 to 1.15). The certainty of the evidence was very low due to high risk of bias and imprecision (<a href="./references#CD013531-fig-0019" title="">Analysis 8.1</a>; <a href="./full#CD013531-tbl-0008">summary of findings Table 8</a>). </p> </section> <section id="CD013531-sec-0105"> <h6 class="title">Withdrawals due to adverse events</h6> <p>There were no withdrawals due to adverse events in either group, so there was no estimable relative effect of the intervention on withdrawals due to adverse events (<a href="./references#CD013531-fig-0020" title="">Analysis 8.2</a>; <a href="./full#CD013531-tbl-0008">summary of findings Table 8</a>). </p> </section> </section> <section id="CD013531-sec-0106"> <h5 class="title">Secondary outcomes</h5> <p>One participant in the 100 mg olorinab group experienced a serious adverse event, which the authors described as unrelated to the intervention. No serious adverse events were reported in the 25 mg olorinab group. </p> <p>Six of eight participants in the 100 mg olorinab group and four of six participants in the 25 mg olorinab group experienced any adverse event. </p> <p>Anxiety/depression was not reported in this study.</p> </section> </section> <section id="CD013531-sec-0107"> <h4 class="title">Relaxation training versus waitlist</h4> <p>One study (n = 56) compared relaxation training to a waitlist (the people in the waitlist would receive the training after the end of the study) (<a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>). The study included CD and UC participants who were at an active stage of the disease according to the "Disease Activity Questionnaire", by meeting one of the following criteria: more than five bowel movements a day, more than one hospitalisation a year over the previous two years, and had either suffered a fistula during the previous year or was using corticosteroids. The length of the intervention was five weeks. </p> <section id="CD013531-sec-0108"> <h5 class="title">Primary outcomes</h5> <p><a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a> did not report on treatment success. Pain was measured on the 0‐to‐10‐centimetre VAS. Pain frequency and withdrawals due to adverse events were not reported. </p> <section id="CD013531-sec-0109"> <h6 class="title">Pain intensity</h6> <p>At end of study the mean (SD) score was 2.23 (1.83) for the relaxation training group and 2.95 (2.44) for the waitlist group. There was no clear difference in pain intensity when relaxation training was compared to a waitlist (MD −0.72, 95% CI −1.85 to 0.41). The certainty of the evidence was very low due to high risk of bias and imprecision (<a href="./references#CD013531-fig-0021" title="">Analysis 9.1</a>; <a href="./full#CD013531-tbl-0009">summary of findings Table 9</a>). </p> </section> </section> <section id="CD013531-sec-0110"> <h5 class="title">Secondary outcomes</h5> <p>Mean (SD) anxiety as measured on the Spielberger’s State‐Trait Anxiety Inventory at end of study was 36.67 (10.65) for the relaxation training group and 40.51 (12.57) for the waitlist group. </p> <p>Mean (SD) depression measured using the 0‐to‐10‐centimetre VAS at end of study was 1.39 (2.23) for the relaxation training group and 1.9 (1.99) for the waitlist group. </p> <p>Serious adverse events or total number of participants with any adverse event was not reported in this study. </p> </section> </section> <section id="CD013531-sec-0111"> <h4 class="title">Web‐based education versus standard book‐based education</h4> <p>One study (n = 60) compared web‐based education to standard book‐based education (<a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>). The study included participants with CD or UC who were in either an active or inactive stage of the disease. The length of the intervention was eight weeks. </p> <section id="CD013531-sec-0112"> <h5 class="title">Primary outcomes</h5> <p><a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a> did not report on treatment success. Pain intensity was measured on the 0‐to‐10‐centimetre VAS. Pain frequency was not reported in this study. </p> <section id="CD013531-sec-0113"> <h6 class="title">Pain intensity</h6> <p>At end of study, the mean (SD) score was 1.8 (2.04) for the web‐based education group and 1.93 (2.39) for the standard book‐based education group. There was no clear difference in pain intensity when web‐based education was compared with standard book‐based education (MD −0.13, 95% CI −1.25 to 0.99). The certainty of the evidence was very low due to unclear risk of bias and imprecision (<a href="./references#CD013531-fig-0022" title="">Analysis 10.1</a>; <a href="./full#CD013531-tbl-0010">summary of findings Table 10</a>). </p> </section> <section id="CD013531-sec-0114"> <h6 class="title">Withdrawals due to adverse events</h6> <p>There were no withdrawals due to adverse events in either group, so there was no estimable relative effect of the intervention on withdrawals due to adverse events (<a href="./references#CD013531-fig-0023" title="">Analysis 10.2</a>; <a href="./full#CD013531-tbl-0010">summary of findings Table 10</a>). </p> </section> </section> <section id="CD013531-sec-0115"> <h5 class="title">Secondary outcomes</h5> <p><a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a> did not report on anxiety/depression, serious adverse events, or total number of participants with any adverse event. </p> </section> </section> <section id="CD013531-sec-0116"> <h4 class="title">Yoga intervention versus no treatment (both groups received standard medical therapy)</h4> <p>One study (n = 100) compared a yoga intervention to no yoga (<a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>). The study only included participants with CD or UC who were at an inactive stage of the disease with a CDAI score &lt; 150; UC activity was measured on the Truelove and Witts Severity Index. The length of the intervention was eight weeks. </p> <section id="CD013531-sec-0117"> <h5 class="title">Primary outcomes</h5> <p>Treatment success in this study was measured as a dichotomous outcome of presence or absence of pain; however, results were reported only for the UC participants and not for CD participants. We contacted the authors for the missing data but received no response. Pain frequency or intensity was not reported. </p> <section id="CD013531-sec-0118"> <h6 class="title">Withdrawals due to adverse events</h6> <p>There were no withdrawals due to adverse events in either group, so there was no estimable relative effect of the intervention on withdrawals due to adverse events (<a href="./references#CD013531-fig-0024" title="">Analysis 11.1</a>; <a href="./full#CD013531-tbl-0011">summary of findings Table 11</a>). </p> </section> </section> <section id="CD013531-sec-0119"> <h5 class="title">Secondary outcomes</h5> <p>The authors reported that no serious adverse events occurred in either group.</p> <p>There was one reported total adverse event in the yoga group (bone fracture).</p> <p>Anxiety level results were presented only for UC and not for CD participants. Depression was not reported. </p> </section> </section> <section id="CD013531-sec-0120"> <h4 class="title">Transcranial direct current stimulation versus sham stimulation</h4> <p>One study (n = 20) compared transcranial direct current stimulation to sham stimulation (<a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>). The study included CD and UC participants who were at an active stage of the disease as measured with either the Simple Clinical Colitis Activity Index for UC participants or Harvey–Bradshaw Index for CD participants. The length of the intervention was five days. </p> <section id="CD013531-sec-0121"> <h5 class="title">Primary outcomes</h5> <p>Treatment success was not reported. Pain was measured on the 0‐to‐10‐centimetre VAS and mechanically on the Pressure Pain Threshold (PPT) via an algometer on the right and left abdomen. Pain frequency was not reported. </p> <section id="CD013531-sec-0122"> <h6 class="title">Pain intensity</h6> <p>At the end of study, the mean (SD) VAS score for pain intensity was 2.8 (2.3) for the transcranial stimulation group and 4.45 (1.3) for the sham stimulation group. Transcranial direct current stimulation may improve pain intensity when compared to sham stimulation (MD −1.65, 95% CI −3.29 to −0.01). The certainty of the evidence was low due to high imprecision (<a href="./references#CD013531-fig-0025" title="">Analysis 12.1</a>; <a href="./full#CD013531-tbl-0012">summary of findings Table 12</a>). </p> </section> <section id="CD013531-sec-0123"> <h6 class="title">Withdrawals due to adverse events</h6> <p>There were no withdrawals due to adverse events in either group, so there was no estimable relative effect of the intervention on withdrawals due to adverse events (<a href="./references#CD013531-fig-0026" title="">Analysis 12.2</a>; <a href="./full#CD013531-tbl-0012">summary of findings Table 12</a>). </p> </section> </section> <section id="CD013531-sec-0124"> <h5 class="title">Secondary outcomes</h5> <p>The authors reported that no serious adverse events occurred in this study. They reported on total adverse events, but as number of incidents rather than number of participants with adverse events. </p> <p>Depression was measured at baseline, but no end‐of‐study results were reported. Anxiety was not reported. </p> </section> </section> <section id="CD013531-sec-0125"> <h4 class="title">Kefir diet (<i>Lactobacillus</i> bacteria) versus no intervention </h4> <p>One study (n = 48) compared a kefir diet with <i>Lactobacillus</i> bacteria to no intervention (<a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>). The study included participants with CD or UC whose disease activity ranged from inactive to moderate. The length of the intervention was four weeks. </p> <section id="CD013531-sec-0126"> <h5 class="title">Primary outcomes</h5> <p><a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a> did not report on treatment success. Pain was measured on a 4‐point rating scale from 0 to 3. Pain frequency was not reported. </p> <section id="CD013531-sec-0127"> <h6 class="title">Pain intensity</h6> <p>At the end of study, mean (SD) pain score for pain intensity was 0.2 (0.63) for the CD kefir group and 1.3 (0.67) for the no‐intervention group. No clear difference was detected in pain intensity scores when kefir diet was compared to no intervention (MD −1.10, 95% CI −1.67 to −0.53). The certainty of the evidence was very low due to unclear risk of bias and imprecision (<a href="./references#CD013531-fig-0027" title="">Analysis 13.1</a>; <a href="./full#CD013531-tbl-0013">summary of findings Table 13</a>). </p> <p>At the end of study, mean (SD) pain score for pain intensity was 0.9 (0.97) for the IBD kefir group and 0.28 (0.61) for the no‐intervention group. No clear difference was detected in pain intensity scores when kefir diet was compared to no intervention (MD 0.62, 95% CI 0.17 to 1.07). The certainty of the evidence was very low due to unclear risk of bias and imprecision (<a href="./references#CD013531-fig-0028" title="">Analysis 13.2</a>; <a href="./full#CD013531-tbl-0013">summary of findings Table 13</a>). </p> </section> <section id="CD013531-sec-0128"> <h6 class="title">Withdrawals due to adverse events</h6> <p>There were no withdrawals due to adverse events in either group, so there was no estimable relative effect of the intervention on withdrawals due to adverse events (<a href="./references#CD013531-fig-0029" title="">Analysis 13.3</a>; <a href="./full#CD013531-tbl-0013">summary of findings Table 13</a>). </p> </section> </section> <section id="CD013531-sec-0129"> <h5 class="title">Secondary outcomes</h5> <p><a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a> did not report on anxiety/depression, serious adverse events, or total number of participants with any adverse event. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013531-sec-0130" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013531-sec-0130"></div> <section id="CD013531-sec-0131"> <h3 class="title" id="CD013531-sec-0131">Summary of main results</h3> <p>This review included a wide range of interventions. Three were forms of diet (<a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>); three were forms of psychological management (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>); two were forms of alternative therapies (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>); two were drug interventions (<a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>); one was an educational intervention (<a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>); one was a form of exercise (<a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>); and one was a form of brain stimulation (<a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>). Five studies looked exclusively at CD (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>), whilst the remaining studies evaluated participants with both CD and UC; two of these studies provided separate data for their CD population (<a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>). The studies included a range of disease states. </p> <p>Only two studies defined or reported our primary outcome of treatment success (<a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>). In the remaining studies pain was only measured as a continuous outcome by improvement on a rating scale: 0‐to‐100 scales (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>); 0‐to‐10‐centimetre VAS or 0‐to‐10 Likert scale (<a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>); 4‐point 0‐to‐3 scale (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>); or a combination of a 3‐point scale and author‐derived formulas (<a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>). In all studies a lower rating indicated less pain, whilst a higher rating indicated more pain. One study measured only the absence or presence of pain as a dichotomous outcome (<a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>). Except for this study, all studies measured pain intensity, whilst only three studies measured pain frequency (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>). Withdrawals due to adverse events were directly or indirectly reported in nine studies (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>). </p> <p>This heterogeneity in outcome measures reported and interventions used severely limited our scope for meta‐analysis. </p> <p>The only low‐certainty evidence found was for the comparison transcranial direct current stimulation versus sham stimulation (<a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>); this evidence showed that there may be an improvement in pain intensity for CD and UC participants (no separate CD data were provided), with direct current stimulation when that was measured using visual analogue scales. </p> <p>In two pooled studies comparing a low FODMAP diet and a sham diet, we found very low‐certainty evidence for a difference between a low FODMAP diet and a sham diet for the outcome pain intensity for CD and UC participants (no separate CD data provided by <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>) (<a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>), therefore no conclusions could be drawn about the efficacy of this intervention in improving pain intensity. </p> <p>In one study comparing stress management to standard treatment and self‐directed stress management to standard treatment (it is unclear whether the stress management interventions replaced standard treatment or were added to standard treatment), we found very low‐certainty evidence for a difference between both stress management and self‐directed stress management in comparison to standard treatment for the outcome pain intensity in CD participants (<a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>), therefore no conclusions could be drawn about the efficacy of these interventions in improving pain intensity. </p> <p>There was no clear difference in pain intensity or frequency between interventions for any other direct comparisons, although the certainty of the evidence was very low due to imprecision from sparse data and risk of bias ratings of unclear and high risk. </p> <p>Of the studies that reported withdrawals due to adverse events, all reported no withdrawals except for <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> and <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>. <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> evaluated a low FODMAP diet versus a sham diet, and <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a> evaluated a drug intervention comparing enteric‐release glyceryl trinitrate to placebo. The two studies showed no clear effect on withdrawals due to adverse events, although the certainty of the evidence was very low due to unclear risk of bias and high imprecision. Lack of evidence prevented us from drawing any conclusions about the effects of the other interventions on withdrawals due to adverse events. </p> <p>The reporting of serious adverse events and total number of participants with any adverse event as secondary outcomes was inconsistent. Seven studies reported on serious adverse events and total number of participants with any adverse event (<a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>; <a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>). The most adverse events were reported in the two drug interventions (<a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>), whilst adverse events tended to be very low or zero in the non‐drug interventions. However, no conclusions could be drawn regarding adverse events for any of the interventions studied due to the low number of events. </p> <p><a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a> measured and reported anxiety and depression at end of study. Three studies mentioned measuring anxiety or depression at baseline, but no anxiety or depression end‐of‐study results were presented in <a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>; no anxiety end‐of‐study results for CD participants were reported in <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; and no depression end‐of‐study results were reported in <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>. Consequently, no meaningful conclusions could be drawn regarding this outcome. </p> </section> <section id="CD013531-sec-0132"> <h3 class="title" id="CD013531-sec-0132">Overall completeness and applicability of evidence</h3> <p>The included studies not only considered a wide range of interventions, but most considered a mix of disease activity and form of IBD. This is rather distinct from the majority of reviewed studies in the wider Cochrane IBD portfolio, which almost always consider UC and CD separately, or at the very least report results for both groups in a single study. Similarly, the reviews reflect a mixture of stage of CD and IBD. As such, the evidence in this review is very different, with a mixture of both conditions and disease states in all papers, which raises significant issues regarding clinical heterogeneity. </p> <p>It is also very clear that, despite there being a reasonable number of included studies, the great range of interventions and the small numbers of included participants leave the individual evidence at significant risk of imprecision. This is pervasive across the evidence presented in this review, with no single comparison not at risk of imprecision. </p> <p>One of the issues experienced when considering the evidence was that, despite our inclusion criteria requiring interventions to be focussed on pain, not all papers provided explicit descriptions of baseline pain. Inclusion criteria could be complex, and therefore pain change scores, as well as clear baseline pain data, are areas which limit the completeness of the evidence for clinical interpretation. </p> <p>The incidence of IBS amongst IBD patients is higher than in people without IBD (<a href="./references#CD013531-bbs2-0064" title="HalpinSJ , FordAC . Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. American Journal of Gastroenterology2012;107(10):1474-82.">Halpin 2012</a>), and it is very difficult to separate whether IBD patients' continuing pain symptoms are related to their previous disease state. Determining what gastrointestinal symptoms are truly functional symptoms is not possible, which may have affected the overall completeness and applicability of our evidence. </p> <p>Another issue was the number of participants with pain at baseline, in order to determine what denominator to use for our analyses. All papers explicitly or close to explicitly included participants with gut symptoms or pain, although in same cases there was a lack of clarity. However, considering this issue pragmatically, all pain outcomes studied were continuous, and therefore used the denominator of all participants randomised, as it would not be statistically sound to do otherwise. One exception was the <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a> trial, which reported a dichotomous pain outcome, but all participants at baseline were experiencing abdominal pain, so again we used the number of all participants randomised as the denominator for our analysis. </p> <p>We also noted the use of multiple scales to measure pain within the same study (<a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a>), or proxy or measures, such as the use of a mechanical algometer to measure pain thresholds (<a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>). It’s important that future studies consider using the same internationally recognised measures for pain, such as visual analogue scales, in order to limit the heterogeneity that might be caused by using a variety of different methodologies. </p> </section> <section id="CD013531-sec-0133"> <h3 class="title" id="CD013531-sec-0133">Quality of the evidence</h3> <p>There were significant issues related to risk of bias in the studies included in this review. Despite our requests to authors of all included studies, we received no data to change our judgements in these key areas. </p> <p>No single comparison surpassed 100 participants as a total, which meant that all outcomes were judged to be highly imprecise, and the certainty of the evidence was downgraded twice for this reason. </p> <p>A number of studies did not clearly describe randomisation, <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>, or allocation concealment, <a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a>; <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>; <a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>; <a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a>; <a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a>. </p> <p>Blinding of participants and personnel was understandably not possible in most of the included studies. However, most studies did not discuss whether their outcome assessors were blinded either. </p> <p>A number of studies had issues with selective reporting (<a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a>; <a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a>; <a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>), leading to further issues related to risk of bias and downgrading of the certainty of the evidence. Attrition bias was also an issue, with three studies judged as unclear risk of bias (<a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>), and one as high risk of bias for this domain (<a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a>). </p> <p>Finally, other key sources of bias were present, mainly a potential imbalance in baseline characteristics, which was observed or was unclear in four studies (<a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a>; <a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a>; <a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a>; <a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a>), and that further impacted the quality of the evidence. </p> </section> <section id="CD013531-sec-0134"> <h3 class="title" id="CD013531-sec-0134">Potential biases in the review process</h3> <p>Clinical heterogeneity is a key area of concern in this review. As previously discussed, the inclusion of studies focusing exclusively on CD patients together with a majority of studies that included CD and UC patients as an indecipherable IBD cohort, as well as the variety of disease states, reflects the evidence as a whole, but ignores the issue of clinical heterogeneity to some extent. It would have been possible to exclude studies that did not differentiate between CD and UC, and this was a discussion point for the team when completing the review. If we decided to exclude these studies from this review, and similarly exclude them from our concomitant UC review, a potentially important body of evidence would have been unaccounted for. We felt that representing this evidence base was vital, together with accepting and transparently presenting the difficulties this led to, related to clinical heterogeneity. On balance, given the extremely limited implications of the current evidence base, we decided to include studies that included CD and UC patients as one IBD cohort and use them for our analysis (we also decided that in our UC review, data exclusively on UC would be included). However, as further data become available, this would not be the approach the team or indeed readers would endorse and is a potential source of bias. As this has not clearly been defined within the original protocol, it must be recognised as a potential source of bias in the review. </p> </section> <section id="CD013531-sec-0135"> <h3 class="title" id="CD013531-sec-0135">Agreements and disagreements with other studies or reviews</h3> <p>This is the first Cochrane Review on this topic.</p> <p>Considering the international guidelines for IBD, few of the major societies mention the treating of pain in IBD. </p> <p>The recent British Society of Gastroenterology guidelines do offer recommendations (<a href="./references#CD013531-bbs2-0053" title="British Society of Gastroenterology. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. www.bsg.org.uk/wp-content/uploads/2019/12/BSG-IBD-Guidelines-2019.pdf (accessed 27 April 2019).">BSG 2019</a>), citing several of the studies included in this review. They state that psychological interventions may be useful as adjunct therapy, describing this as a weak recommendation with low‐quality evidence, which would be supported by the evidence in this review. They do not define such psychological interventions, and do not comment on any of the other intervention types included in this review. </p> <p>The current UK National Institute for Health and Care Excellence (NICE) guidelines do not discuss pain relief as a standalone treatment goal (<a href="./references#CD013531-bbs2-0072" title="National Institute for Health and Care Excellence. Crohn's disease: management. www.nice.org.uk/guidance/ng129 (accessed 1 July 2019).">NICE 2019</a>). The American Gastroenterological Association guidelines make no mention of guidelines in this area (<a href="./references#CD013531-bbs2-0050" title="American Gastroenterological Association. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti–TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. www.gastrojournal.org/article/S0016-5085(13)01521-7/fulltext (accessed 27 April 2020).">AGA 2020</a>). </p> <p>The European Crohn's and Colitis Organisation guidelines also do not mention therapies in this area (<a href="./references#CD013531-bbs2-0057" title="European Crohn’s and Colitis Organisation. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. academic.oup.com/ecco-jcc/article/14/1/4/5620479 (accessed 27 April 2020).">ECCO 2020</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013531-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013531-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013531-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013531-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low FODMAP diet versus sham diet, Outcome 1: Pain frequency defined by days of pain by IBS‐SSS scores (0 to 100) for IBD" data-id="CD013531-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Low FODMAP diet versus sham diet, Outcome 1: Pain frequency defined by days of pain by IBS‐SSS scores (0 to 100) for IBD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low FODMAP diet versus sham diet, Outcome 2: Days with moderate or severe pain by GSRS scores for IBD (0 to 3) for IBD" data-id="CD013531-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Low FODMAP diet versus sham diet, Outcome 2: Days with moderate or severe pain by GSRS scores for IBD (0 to 3) for IBD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low FODMAP diet versus sham diet, Outcome 3: Pain frequency defined by days of pain by IBS‐SSS scores (0 to 100) for CD" data-id="CD013531-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Low FODMAP diet versus sham diet, Outcome 3: Pain frequency defined by days of pain by IBS‐SSS scores (0 to 100) for CD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low FODMAP diet versus sham diet, Outcome 4: Pain intensity IBD (0 to 100)" data-id="CD013531-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Low FODMAP diet versus sham diet, Outcome 4: Pain intensity IBD (0 to 100) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low FODMAP diet versus sham diet, Outcome 5: Pain intensity IBD (0 to 3)" data-id="CD013531-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Low FODMAP diet versus sham diet, Outcome 5: Pain intensity IBD (0 to 3) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low FODMAP diet versus sham diet, Outcome 6: Pain intensity CD (0 to 100)" data-id="CD013531-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Low FODMAP diet versus sham diet, Outcome 6: Pain intensity CD (0 to 100) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low FODMAP diet versus sham diet, Outcome 7: Withdrawals due to adverse events" data-id="CD013531-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Low FODMAP diet versus sham diet, Outcome 7: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Medicine‐separated moxibustion combined with acupuncture versus wheat bran‐separated moxibustion combined with shallow acupuncture, Outcome 1: Withdrawals due to adverse events" data-id="CD013531-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Medicine‐separated moxibustion combined with acupuncture versus wheat bran‐separated moxibustion combined with shallow acupuncture, Outcome 1: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Mindfulness with cognitive behavioural therapy (CBT) versus no treatment (both groups received standard medical therapy), Outcome 1: Pain frequency and severity of abdominal discomfort, severity of abdominal bloating, satisfaction with bowel habit, and impact of symptoms on life in general" data-id="CD013531-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Mindfulness with cognitive behavioural therapy (CBT) versus no treatment (both groups received standard medical therapy), Outcome 1: Pain frequency and severity of abdominal discomfort, severity of abdominal bloating, satisfaction with bowel habit, and impact of symptoms on life in general </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Mindfulness with cognitive behavioural therapy (CBT) versus no treatment (both groups received standard medical therapy), Outcome 2: Withdrawals due to adverse events" data-id="CD013531-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Mindfulness with cognitive behavioural therapy (CBT) versus no treatment (both groups received standard medical therapy), Outcome 2: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: soft non‐manipulative osteopathic treatment versus no intervention, Outcome 1: Pain intensity" data-id="CD013531-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: soft non‐manipulative osteopathic treatment versus no intervention, Outcome 1: Pain intensity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: soft non‐manipulative osteopathic treatment versus no intervention, Outcome 2: Withdrawals due to adverse events" data-id="CD013531-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: soft non‐manipulative osteopathic treatment versus no intervention, Outcome 2: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Directed stress management versus standard treatment, Outcome 1: Pain intensity" data-id="CD013531-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Directed stress management versus standard treatment, Outcome 1: Pain intensity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Self‐directed stress management vs conventional therapy, Outcome 1: Pain intensity" data-id="CD013531-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Self‐directed stress management vs conventional therapy, Outcome 1: Pain intensity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Enteric‐release glyceryl trinitrate versus placebo, Outcome 1: Withdrawals due to adverse events" data-id="CD013531-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Enteric‐release glyceryl trinitrate versus placebo, Outcome 1: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: 100 mg olorinab 3 times/day versus 25 mg olorinab 3 times/day, Outcome 1: Pain intensity" data-id="CD013531-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: 100 mg olorinab 3 times/day versus 25 mg olorinab 3 times/day, Outcome 1: Pain intensity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: 100 mg olorinab 3 times/day versus 25 mg olorinab 3 times/day, Outcome 2: Withdrawals due to adverse events" data-id="CD013531-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: 100 mg olorinab 3 times/day versus 25 mg olorinab 3 times/day, Outcome 2: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Relaxation training versus waitlist, Outcome 1: Pain intensity" data-id="CD013531-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Relaxation training versus waitlist, Outcome 1: Pain intensity</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Web‐based education versus standard book‐based education, Outcome 1: Pain intensity" data-id="CD013531-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Web‐based education versus standard book‐based education, Outcome 1: Pain intensity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Web‐based education versus standard book‐based education, Outcome 2: Withdrawals due to adverse events" data-id="CD013531-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Web‐based education versus standard book‐based education, Outcome 2: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Yoga intervention versus no treatment (both groups received standard medical therapy), Outcome 1: Withdrawals due to adverse events" data-id="CD013531-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Yoga intervention versus no treatment (both groups received standard medical therapy), Outcome 1: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Transcranial direct current stimulation versus sham stimulation, Outcome 1: Pain intensity (0 to 100)" data-id="CD013531-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Transcranial direct current stimulation versus sham stimulation, Outcome 1: Pain intensity (0 to 100) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Transcranial direct current stimulation versus sham stimulation, Outcome 2: Withdrawals due to adverse events" data-id="CD013531-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Transcranial direct current stimulation versus sham stimulation, Outcome 2: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Kefir versus no intervention, Outcome 1: CD pain intensity (0 to 3)" data-id="CD013531-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Kefir versus no intervention, Outcome 1: CD pain intensity (0 to 3)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Kefir versus no intervention, Outcome 2: IBD pain intensity (0 to 3)" data-id="CD013531-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Kefir versus no intervention, Outcome 2: IBD pain intensity (0 to 3)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013531-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/urn:x-wiley:14651858:media:CD013531:CD013531-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Kefir versus no intervention, Outcome 3: Withdrawals due to adverse events" data-id="CD013531-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_t/tCD013531-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Kefir versus no intervention, Outcome 3: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/media/CDSR/CD013531/image_n/nCD013531-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013531-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Low FODMAP diet compared to sham diet for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Low FODMAP diet compared to sham diet for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease<br/><b>Setting:</b> multicentre, 2 gastroenterology clinics in the UK and an unstated setting in Italy<br/><b>Intervention:</b> low FODMAP diet<br/><b>Comparison:</b> sham diet </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sham diet</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with low FODMAP diet</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Note measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain frequency IBD (measured in days of pain on the IBS‐SSS questionnaire)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2 lower<br/>(15.86 lower to 11.86 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain frequency IBD (measured in days with moderate or severe pain on the GSRS questionnaire)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.4 higher<br/>(0.44 lower to 1.24 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain frequency CD (measured in days of pain on the IBS‐SSS questionnaire)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 12 lower<br/>(114.55 lower to 90.55 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity IBD (0‐10cm visual analogue scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 8.46 lower<br/>(15.76 lower to 1.16 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity IBD (0‐3 point GSRS scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 8 lower<br/>(66.27 lower to 50.27 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity CD (0‐10cm visual analogue scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.2 higher<br/>(8.67 lower to 9.07 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7.4 per 1000</p> <p>(1 to 77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.85 (0.18 to 19.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CD:</b> Crohn's disease; <b>CI:</b> confidence interval; <b>FODMAP:</b> fermentable oligo‐, di‐, monosaccharides and polyols; <b>GSRS:</b> Gastrointestinal Symptom Rating Scale; <b>IBD:</b> inflammatory bowel disease; <b>IBS‐SSS:</b> Irritable Bowel Syndrome Severity Scoring System; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias.<br/><sup>b</sup>Downgraded two levels due to imprecision from very sparse data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Low FODMAP diet compared to sham diet for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013531-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Medicine‐separated moxibustion combined with acupuncture compared with wheat bran‐separated moxibustion combined with shallow acupuncture for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Medicine‐separated moxibustion combined with acupuncture compared with wheat bran‐separated moxibustion combined with shallow acupuncture for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with Crohn's disease </p> <p><b>Settings:</b> Shanghai Acupuncture Meridian Institute Medical Clinic Acupuncture Inflammatory Bowel Disease Specialist Clinic, Zhongshan Hospital Affiliated Endoscopic Center, and Yueyang Hospital, Shanghai University of Traditional Chinese Medicine </p> <p><b>Intervention:</b> medicine‐separated moxibustion combined with acupuncture </p> <p><b>Comparison:</b> wheat bran‐separated moxibustion combined with shallow acupuncture </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with wheat bran‐separated moxibustion combined with shallow acupuncture</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with medicine‐separated moxibustion combined with acupuncture</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain frequency or change in frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain intensity or change in intensity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to imprecision from very sparse data.<br/><sup>b</sup>Downgraded one level due to risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Medicine‐separated moxibustion combined with acupuncture compared with wheat bran‐separated moxibustion combined with shallow acupuncture for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013531-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Mindfulness with cognitive behavioural therapy (CBT) compared with no treatment (both groups received standard medical therapy) for the management of abdominal pain in Crohn's Disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Mindfulness with cognitive behavioural therapy (CBT) versus no treatment (both groups received standard medical therapy) for the management of abdominal pain in Crohn's Disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease<br/><b>Setting:</b> multicentre, hospitals in the UK<br/><b>Intervention:</b> mindfulness with CBT<br/><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard medical therapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with mindfulness with CBT + standard medical therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain frequency and intensity (measured as part of the 0‐500 point IBS‐SSS questionnaire)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 37 lower<br/>(87.29 lower to 13.29 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CBT:</b> cognitive behavioural therapy; <b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to imprecision from very sparse data.<br/><sup>b</sup>Downgraded one level due to risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Mindfulness with cognitive behavioural therapy (CBT) compared with no treatment (both groups received standard medical therapy) for the management of abdominal pain in Crohn's Disease and inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013531-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">soft non‐manipulative osteopathic treatment compared to no intervention for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Soft non‐manipulative osteopathic treatment compared to no intervention for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with Crohn's disease<br/><b>Setting:</b> single centre, hospital in Spain<br/><b>Intervention:</b> soft non‐manipulative osteopathic<br/><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with soft non‐manipulative osteopathic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain frequency or change in frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity (0‐10cm visual analogue scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 higher<br/>(1.81 lower to 1.83 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to imprecision from very sparse data.<br/><sup>b</sup>Downgraded one level due to risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">soft non‐manipulative osteopathic treatment compared to no intervention for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013531-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Directed stress management (it is unclear whether these interventions replaced standard treatment or were added to standard treatment) versus standard treatment for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Stress management (it is unclear whether these interventions replaced standard treatment or were added to standard treatment) versus standard treatment for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with Crohn's disease<br/><b>Setting:</b> single centre, Inflammatory Intestinal Disease Unit of Asturias Central Hospital, Spain<br/><b>Intervention:</b> stress management<br/><b>Comparison:</b> no stress management </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no stress management</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with stress management</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain frequency or change in pain frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity (author‐derived formula based on a 1‐3 point scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 34.3 lower<br/>(61.99 lower to 6.61 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawals due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to imprecision from very sparse data.<br/><sup>b</sup>Downgraded one level due to risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Directed stress management (it is unclear whether these interventions replaced standard treatment or were added to standard treatment) versus standard treatment for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013531-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Self‐directed stress management (it is unclear whether these interventions replaced standard treatment or were added to standard treatment) versus standard treatment for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Self‐directed stress management (it is unclear whether these interventions replaced standard treatment or were added to standard treatment) versus standard treatment for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with Crohn's disease<br/><b>Setting:</b> single centre, Inflammatory Intestinal Disease Unit of Asturias Central Hospital, Spain<br/><b>Intervention:</b> stress management<br/><b>Comparison:</b> no stress management </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no stress management</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with stress management</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain frequency or change in pain frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity  (author‐derived formula based on a 1‐3 point scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 30.5 lower<br/>(58.45 lower to 2.55 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low<sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawals due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to imprecision from very sparse data.<br/><sup>b</sup>Downgraded one level due to risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Self‐directed stress management (it is unclear whether these interventions replaced standard treatment or were added to standard treatment) versus standard treatment for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013531-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Enteric‐release glyceryl trinitrate compared to placebo for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Enteric‐release glyceryl trinitrate compared to placebo for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with Crohn's disease<br/><b>Setting:</b> unstated (centres in the UK)<br/><b>Intervention:</b> enteric‐release glyceryl trinitrate<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with enteric‐release glyceryl trinitrate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain frequency or change in frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain intensity or change in intensity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.18<br/>(0.94 to 10.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>IG: Headache = 1, worsening clinical condition = 4, generalised rash = 1, mood change/irritability = 1, loss of consciousness/memory = 1 </p> <p>CG: Headache = 2, worsening clinical condition = 1</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265 per 1000<br/>(78 to 897) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias.<br/><sup>b</sup>Downgraded two levels due to imprecision from very sparse data. </p> <p>IG: Intervention group</p> <p>CG: Control group</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Enteric‐release glyceryl trinitrate compared to placebo for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013531-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">100 mg olorinab 3 times/day compared to 25 mg olorinab 3 times/day for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>100 mg olorinab 3 times/day compared to 25 mg olorinab 3 times/day for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with Crohn's disease<br/><b>Setting:</b> unstated (multicentre, USA)<br/><b>Intervention:</b> 100 mg olorinab 3 times/day<br/><b>Comparison:</b> 25 mg olorinab 3 times/day </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with 25 mg olorinab 3 times/day</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with 100 mg olorinab 3 times/day</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain frequency or change in pain frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain intensity (30% reduction in weekly AAPS)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/>(0.38 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>660 per 1000<br/>(380 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias.<br/><sup>b</sup>Downgraded two levels due to imprecision from very sparse data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">100 mg olorinab 3 times/day compared to 25 mg olorinab 3 times/day for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013531-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Relaxation training compared to waitlist for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Relaxation training compared to waitlist for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease<br/><b>Setting:</b> Hadassah Medical Center in Jerusalem<br/><b>Intervention:</b> relaxation training<br/><b>Comparison:</b> waitlist </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with waitlist</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with relaxation training</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain frequency or change in pain frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity (0‐10cm visual analogue scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.72 lower<br/>(1.85 lower to 0.41 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawals due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias.<br/><sup>b</sup>Downgraded two levels due to imprecision from very sparse data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Relaxation training compared to waitlist for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013531-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Web‐based education compared to standard book‐based education for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Web‐based education compared to standard book‐based education for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease<br/><b>Setting:</b> single centre, gastroenterology unit in Turkey<br/><b>Intervention:</b> web‐based education<br/><b>Comparison:</b> standard book‐based education </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard book‐based education</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with web‐based education</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain frequency or change in frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity (0‐10cm visual analogue scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.13 lower<br/>(1.25 lower to 0.99 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias.<br/><sup>b</sup>Downgraded two levels due to imprecision from very sparse data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Web‐based education compared to standard book‐based education for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013531-tbl-0011"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Yoga intervention compared to no treatment (both groups received standard medical therapy) for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Yoga intervention compared to no treatment (both groups received standard medical therapy) for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with inflammatory bowel disease </p> <p><b>Settings:</b> single centre, All India Institute of Medical Science (AIIMS), New Delhi, India </p> <p><b>Intervention:</b> yoga </p> <p><b>Comparison:</b> no yoga </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard medical therapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with yoga plus standard medical therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain frequency or change in frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain intensity or change in intensity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias.<br/><sup>b</sup>Downgraded two levels due to imprecision from very sparse data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Yoga intervention compared to no treatment (both groups received standard medical therapy) for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013531-tbl-0012"> <div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Transcranial direct current stimulation compared to sham stimulation for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Transcranial direct current stimulation compared to sham stimulation for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with inflammatory bowel disease<br/><b>Setting:</b> single centre, Medical Department I (Gastroenterology, Infectious Diseases, Rheumatology) of the Charite‐Campus Benjamin Franklin, Germany<br/><b>Intervention:</b> transcranial direct current stimulation<br/><b>Comparison:</b> sham stimulation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sham stimulation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with transcranial direct current stimulation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain frequency or change in frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity (0‐10cm visual analogue scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.65 lower<br/>(3.29 lower to 0.01 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low <sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>PPT:</b> Pressure Pain Threshold </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to imprecision from very sparse data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Transcranial direct current stimulation compared to sham stimulation for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013531-tbl-0013"> <div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Kefir ( Lactobacillus bacteria) compared to no intervention for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Kefir (<i>Lactobacillus</i> bacteria) compared to no intervention for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with inflammatory bowel disease </p> <p><b>Setting:</b> unstated (single centre, Turkey) </p> <p><b>Intervention:</b> kefir </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with kefir</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment success as defined by the authors</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain frequency or change in frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity IBD  (4‐point rating scale from 0 to 3)</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.62 higher<br/>(0.17 higher to 1.07 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>very low <sup>a b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity CD (4‐point rating scale from 0 to 3)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> <p> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.10 lower<br/>(1.67 lower to 0.53 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>a b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CD:</b> Crohn's disease; <b>CI:</b> confidence interval; <b>IBD:</b> inflammatory bowel disease; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias.<br/><sup>b</sup>Downgraded two levels due to imprecision from very sparse data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Kefir ( Lactobacillus bacteria) compared to no intervention for the management of abdominal pain in Crohn's disease and inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013531-tbl-0014"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Primary outcome details</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Disease type</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Disease activity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Length of intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Measurement of pain</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of randomised participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low FODMAP diet vs sham diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD/IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain frequency and intensity:</p> <p>IBS‐SSS for pain rating scale 0 to 100,</p> <p>GSRS rating scale 0 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> <p>(IG: 27; CG: 25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low FODMAP diet vs sham diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>VAS rating scale 0 to 10 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(IG: 10; CG: 20)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low FODMAP diet vs high FODMAP/normal diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks cross‐over (4 weeks x 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>VAS rating scale 0 to 10 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> <p>(IG: 25; CG: 25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medicine‐separated moxibustion combined with acupuncture vs wheat bran‐separated moxibustion combined with shallow acupuncture </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain frequency and intensity:</p> <p>Traditional Chinese Medicine rating scale 0 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> <p>(IG: 51; CG: 51)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mindfulness with CBT + standard medical therapy vs standard medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain frequency and severity of abdominal discomfort, severity of abdominal bloating, satisfaction with bowel habit, and impact of symptoms on life in general. Each domain is scored 0 to 100, and an overall score of 0 to 500 is obtained. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> <p>(IG: 33; CG: 33)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Soft non‐manipulative osteopathic vs no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>VAS rating scale 0 to 10 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(IG: 16; CG: 14)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stress management vs self‐directed stress management vs standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>rating scale 1 to 3 and author formulas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(IG1: 15; IG2: 15; CG: 15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric‐release glyceryl trinitrate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>rating scale 0 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> <p>(IG: 34; CG: 36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg olorinab 3 times/day vs 25 mg olorinab 3 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive to mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>AAPS of 0‐to‐10 Likert scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> <p>(IG: 8; CG: 6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relaxation training vs waitlist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>VAS rating scale 0 to 10 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> <p>(IG: 28; CG: 28)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based education vs standard book‐based education</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mix of active and inactive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>VAS rating scale 0 to 10 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> <p>(IG: 10; CG: 10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yoga intervention + standard medical therapy vs standard medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence or absence of pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> <p>(IG: 50; CG: 50)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transcranial direct current stimulation vs sham stimulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>Pressure Pain Threshold taken with algometer,</p> <p>VAS rating scale 0 to 10 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> <p>(IG: 10; CG: 10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kefir diet (<i>Lactobacillus</i> bacteria) vs no intervention </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD/IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity:</p> <p>rating scale 0 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> <p>(IG: 28; CG: 20)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>AAPS: average abdominal pain score</p> <p>CBT: cognitive behavioural therapy</p> <p>CD: Crohn's disease</p> <p>CG: control group</p> <p>FODMAP: fermentable oligo‐, di‐, monosaccharides and polyols</p> <p>IG: intervention group</p> <p>GSRS: Gastrointestinal Symptom Rating Scale</p> <p>IBD: inflammatory bowel disease</p> <p>IBS‐SSS: Irritable Bowel Syndrome Severity Scoring System</p> <p>VAS: visual analogue scale</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Primary outcome details</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013531-tbl-0015"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Primary outcome data</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment success end of study data IG/CG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain frequency end of study data IG/CG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain intenstiy end of study data IG/CG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events IG/CG</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low FODMAP diet vs sham diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0003" title="CoxSR , LindsayJO , FromentinS , StaggAJ , McCarthyNE , GalleronN , et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology2020;158:176-88. ISRCTN17061468. Dietary Interventions in inflammatory bowel disease (IBD). www.isrctn.com/ISRCTN17061468 (first received 20 January 2016). ">Cox 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IBS‐SSS all participants  mean(SD)</p> <p>IG= 36(26); CG= 38(25)</p> <p> </p> <p>IBS‐SSS CD mean (SD)</p> <p>IG = 36(138.4); CG=48(128.2)</p> <p> </p> <p>GSRS all participants mean(SD) </p> <p>IG= 1.5(1.6); CG= 1.1(1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IBS‐SSS all participants  mean(SD)</p> <p>IG=22(15.6) ; CG=30(15)</p> <p> </p> <p>IBS‐SSS CD mean (SD)</p> <p>IG = 24(82.3); CG= 32(69.3)</p> <p> </p> <p>GSRS all participants mean(SD) </p> <p>IG=0.9(2.6) ; CG= 0.7(22.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG: 2</p> <p>CG: 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low FODMAP diet vs sham diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0011" title="TapeteG , De BortoliN , CeccarelliL , MumoloMG , VinciE , AlbanoE , et al. Low-FODMAPs diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease2018;50(2):e195. ">Tapete 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean(SD): IG=3.3 (1.9)</p> <p>CG= 4.3(2.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low FODMAP diet vs high FODMAP/normal diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0012" title="TapeteG , CeccarelliL , De BortoliN , BertaniL , AlbanoE , Baiano SvizzeroG . Low- versus high- FODMAPs diet in controlling residual abdominal symptoms in inflammatory bowel disease patients: a randomised controlled study with crossing over. Digestive and Liver Disease2019;51:e219. ">Tapete 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean(SD): IG=1.1(1.6)</p> <p>CG=3.1(2.3)</p> <p>(unclear if average of both cross‐over arms or from the first or second phase of the cross‐over) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medicine‐separated moxibustion combined with acupuncture vs wheat bran‐separated moxibustion combined with shallow acupuncture </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0001" title="BaoC , WuL , WuH , LiuH , ZhaoJ , ZengX , et al. Active Crohn's disease treated with acupuncture and moxibustion: a randomized controlled trial. Chinese Acupuncture &amp; Moxibustion2016;36(7):683-8. ">Bao 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean (no SD provided)</p> <p>IG=0</p> <p>CG=0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean (no SD provided)</p> <p>IG=2</p> <p>CG=1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=0</p> <p>CG=0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mindfulness with CBT + standard medical therapy vs standard medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0002" title="BerrillJW , SadlierM , HoodK , GreenJT . Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. Journal of Crohn's &amp; Colitis2014;8(9):945-55. ">Berrill 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Frequency and intensity measured together as part of the IBS‐SSS score mean(SD)</p> <p>IG= 187 (97)</p> <p>CG= 224 (111)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=0</p> <p>CG=0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Soft non‐manipulative osteopathic vs no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0004" title="Espí-LópezGV , InglésM , Soliva-CazabánI , Serra-AñóP . Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: a randomized controlled trial. Medicine2018;97(51):e13811. ">Espi Lopez 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean(SD): IG=2.72(2.66)</p> <p>CG=2.71(2.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=0</p> <p>CG=0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stress management vs self‐directed stress management vs standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0005" title="Garcia-VegaE , Fernandez-RodriguezC . A stress management programme for Crohn's disease. Behaviour Research and Therapy2004;42(4):367-83. ">Garcia‐Vega 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean(SD): IG=13.3(28)</p> <p>CG=47.6(47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric‐release glyceryl trinitrate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0006" title="HawkesND , RichardsonC , Ch'NgCL , GreenJT , EvansBK , WilliamsJ . Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology &amp; Therapeutics2001;15(12):1867-73. ">Hawkes 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean(no SD presented)</p> <p>IG=8.1</p> <p>CG=8.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=9</p> <p>CG=3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg olorinab 3 times/day vs 25 mg olorinab 3 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0007" title="HigginsP , GinsburgD , GilderK , GilderK , WalshB , EnglishB , et al. Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and Colitis2019;13:S318. LindstromB , RuckleJ , TurnerS , StauberK , BrierleySM , EnglishBA . Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development. Inflammatory Bowel Diseases2019;25 Suppl 1:S318. YacyshynB , GinsbergDC , GilderK , WalshB , EnglishB , TurnerSA , et al. Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Gastroenterology2019;156(6):S665. ">Higgins 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ≥ 30% reduction in weekly AAPS</p> <p>IG: 5 </p> <p>CG: 6 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 hours postdose mean(SD could not be calculated from figure)</p> <p>IG=1.9</p> <p>CG= 1.9</p> <p> </p> <p>Mean change in AAPS (no SD)</p> <p>IG= ‐4.6</p> <p>CG= ‐4.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=0</p> <p>CG=0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relaxation training vs waitlist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0008" title="MizrahiMC , Reicher-AtirR , LevyS , HaramatiS , WengrowerD , IsraeliE , et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology &amp; Health2012;27(12):1463-79. ">Mizrahi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean(SD): IG= 2.23(1.83)</p> <p>CG= 2.95(2.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Web‐based education vs standard book‐based education</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0009" title="Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management, and quality of life on patients with inflammatory bowel disease. Journal of Crohn's and Colitis2018;12(Suppl 1):S582. Ozgursoy UranBN , YildirimY , Senuzun AykarF , UnsalB . The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study. Medical Science2019;23(98):418-31. ">Ozgursoy Uran 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean(SD): IG= 1.8(2.04)</p> <p>CG= 1.93(2.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=0</p> <p>CG=0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yoga intervention + standard medical therapy vs standard medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0010" title="SharmaP , PoojaryG , DwivediSN , DeepakKK . Effect of yoga-based intervention in patients with inflammatory bowel disease. International Journal of Yoga Therapy2015;25(1):101-12. ">Sharma 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=0</p> <p>CG=0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transcranial direct current stimulation vs sham stimulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0013" title="DRKS00005852. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005852 (first received 18 December 2015). NCT02048137. Transcranial direct current stimulation to reduce chronic pain in patients with chronic inflammatory bowel diseases (tDCS in IBD). clinicaltrials.gov/ct2/show/NCT02048137 (first received 29 January 2014). PruessMS , FarmerA , SiegmundB . Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation. Journal of Crohn's and Colitis2016;10:S289-90. VolzMS , FarmerA , SiegmundB . Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. Pain2016;157(2):429-37. ">Volz 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean(SD): IG= 2.8(2.3)</p> <p>CG= 4.45(1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=0</p> <p>CG=0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kefir diet (<i>Lactobacillus</i> bacteria) vs no intervention </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013531-bbs2-0014" title="YilmazI , DolarME , OzpinarH . Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology2019;30(3):242-53. ">Yilmaz 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CD pain intensity mean(SD)</p> <p>IG= 0.2(0.63)</p> <p>CG= 1.3(0.67)</p> <p> </p> <p>IBD pain intensity mean(SD)</p> <p>IG= 0.9(0.97)</p> <p>CG= 0.28(0.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IG=0</p> <p>CG=0</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>AAPS: average abdominal pain score</p> <p>CBT: cognitive behavioural therapy</p> <p>CD: Crohn's disease</p> <p>CG: control group</p> <p>FODMAP: fermentable oligo‐, di‐, monosaccharides and polyols</p> <p>IG: intervention group</p> <p>GSRS: Gastrointestinal Symptom Rating Scale</p> <p>IBD: inflammatory bowel disease</p> <p>IBS‐SSS: Irritable Bowel Syndrome Severity Scoring System</p> <p>VAS: visual analogue scale</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Primary outcome data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/full#CD013531-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013531-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Low FODMAP diet versus sham diet</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Pain frequency defined by days of pain by IBS‐SSS scores (0 to 100) for IBD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐15.86, 11.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Days with moderate or severe pain by GSRS scores for IBD (0 to 3) for IBD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.44, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Pain frequency defined by days of pain by IBS‐SSS scores (0 to 100) for CD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.00 [‐114.55, 90.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Pain intensity IBD (0 to 100) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.46 [‐15.76, ‐1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Pain intensity IBD (0 to 3) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐8.67, 9.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Pain intensity CD (0 to 100) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.00 [‐66.27, 50.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [0.18, 19.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Low FODMAP diet versus sham diet</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013531-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Medicine‐separated moxibustion combined with acupuncture versus wheat bran‐separated moxibustion combined with shallow acupuncture</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Medicine‐separated moxibustion combined with acupuncture versus wheat bran‐separated moxibustion combined with shallow acupuncture</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013531-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Mindfulness with cognitive behavioural therapy (CBT) versus no treatment (both groups received standard medical therapy)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Pain frequency and severity of abdominal discomfort, severity of abdominal bloating, satisfaction with bowel habit, and impact of symptoms on life in general <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐37.00 [‐87.29, 13.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Mindfulness with cognitive behavioural therapy (CBT) versus no treatment (both groups received standard medical therapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013531-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">soft non‐manipulative osteopathic treatment versus no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Pain intensity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐1.81, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">soft non‐manipulative osteopathic treatment versus no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013531-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Directed stress management versus standard treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Pain intensity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐34.30 [‐61.99, ‐6.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Directed stress management versus standard treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013531-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Self‐directed stress management vs conventional therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Pain intensity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐30.50 [‐58.45, ‐2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Self‐directed stress management vs conventional therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013531-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Enteric‐release glyceryl trinitrate versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.18 [0.94, 10.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Enteric‐release glyceryl trinitrate versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013531-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">100 mg olorinab 3 times/day versus 25 mg olorinab 3 times/day</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Pain intensity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.38, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">100 mg olorinab 3 times/day versus 25 mg olorinab 3 times/day</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013531-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Relaxation training versus waitlist</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Pain intensity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.72 [‐1.85, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Relaxation training versus waitlist</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013531-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Web‐based education versus standard book‐based education</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Pain intensity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐1.25, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Web‐based education versus standard book‐based education</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013531-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Yoga intervention versus no treatment (both groups received standard medical therapy)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Yoga intervention versus no treatment (both groups received standard medical therapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013531-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Transcranial direct current stimulation versus sham stimulation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Pain intensity (0 to 100) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.65 [‐3.29, ‐0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Transcranial direct current stimulation versus sham stimulation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013531-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Kefir versus no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 CD pain intensity (0 to 3) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐1.67, ‐0.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 IBD pain intensity (0 to 3) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.17, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Kefir versus no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013531.pub2/references#CD013531-tbl-0028">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013531.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013531-note-0027">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013531-note-0025">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013531-note-0026">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013531-note-0024">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD013531-note-0022">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013531-note-0023">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD013531-note-0021">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013531-note-0020">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013531\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013531\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013531\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013531\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013531\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013531\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013531\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013531\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013531\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013531\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013531\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013531\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013531\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013531\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013531\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013531\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013531\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013531\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Nio3SV1W&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013531.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013531.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013531.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013531.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013531.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729235879"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013531.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729235883"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013531.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed7f4a8f7f55b',t:'MTc0MDcyOTIzNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 